Nucleic acid molecule, recombinant baculovirus containing same and application thereof

By inserting an exogenous gene expression box on the baculovirus genome, recombinant baculovirus is constructed using baculovirus conserved loci sites, the problems of instability of exogenous gene expression and defects interfering with virus occupation are solved, and the exogenous genes are realized Long-term stable passage and high expression.

CN118956966APending Publication Date: 2024-11-15OBIO TECH (SHANGHAI) CORP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411103509.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-17
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the traditional recombinant baculovirus expression system, exogenous gene expression is unstable, and defect interference viruses gradually gain the advantage in the passage process, resulting in a decrease in the expression of exogenous genes and making it difficult to achieve long-term stable passage.

Method used

By designing specific nucleic acid molecules, including the exogenous gene expression box between nucleic acid fragments 1 and 2, the exogenous fragments are inserted using baculovirus conserved loci, including selecting marker genes and target genes, and constructing them using homologous recombination technology Recombinant baculovirus ensures stability and high expression of the genome.

Benefits of technology

Long-term stable passage and high expression of exogenous genes are achieved, new exogenous fragment insertion sites are provided, the stability of the baculovirus genome is improved, and the reliability of the exogenous gene expression system is enhanced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956966A_ABST
    Figure CN118956966A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a nucleic acid molecule, a recombinant baculovirus containing the nucleic acid molecule and application of the recombinant baculovirus. The nucleic acid molecule comprises a nucleic acid fragment 1, a nucleic acid fragment 2 and an exogenous gene expression cassette which is positioned between the nucleic acid fragment 1 and the nucleic acid fragment 2 and is used for expressing an exogenous fragment, complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are tail-to-tail gene pairs; the nucleic acid fragment 1 and the nucleic acid fragment 2 are connected with a non-coding region, the 5'tail end of the non-coding region is taa, the 3 'tail end of the non-coding region is tta, and the exogenous fragment is inserted between taa and tta. New insertion sites of the exogenous fragments are found on the baculovirus genome, when the exogenous fragments are inserted into the insertion sites, baculovirus replication is not affected, passage is stable, and a new choice is provided for effective insertion in the BEV genome in a baculovirus expression system.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application with application number 202410459550.3, application date April 17, 2024, and invention name “Nucleic acid molecules, recombinant baculovirus containing the same and their applications”. Technical Field

[0002] The present application belongs to the field of biomedicine, specifically relates to the technology of modifying viral vectors, and in particular to a nucleic acid molecule, a recombinant baculovirus containing the same, and applications thereof. Background Art

[0003] The insect cell expression system (also known as the recombinant baculovirus expression system) is a eukaryotic expression system that can express foreign genes from a variety of species, including fungi, bacteria, viruses, and plants, in insect cells. The insect cell expression system offers advantages such as high recombinant protein expression, comprehensive post-translational protein modification, suitability for large-scale production, and low production costs. It has been widely used for the expression of various recombinant proteins, drug development, and the production of commercial biological products such as drugs and vaccines.

[0004] The Bac-to-Bac system is widely used in traditional recombinant baculovirus expression systems. Luckow et al., the earliest developers of this system, selected the polyhedron gene (polh) site of the baculovirus as the recombination site of the Tn7 transposon. Insertion of exogenous genes into this locus can usually achieve high expression levels (Luckow et al., 1993, J. Virol. 67(8): 4566-4579). Studies have reported that during the passage of BEV in insect baculovirus expression systems, defective interfering viruses with missing genes are generated. These defective interfering viruses gradually become dominant during the passage, resulting in decreased expression of exogenous genes (Pijlman et al., J Gen Virol, 2003, 84: 2041-2049). Factors contributing to the instability of exogenous genes in the BEV genome include the instability of the exogenous genes themselves, the insertion of DNA fragments, the site of insertion, and the selectivity of different cell environments for defective viruses (Willemsen et al., Virus Evol, 2019, 5(2): vez045). Studies have reported that when the Tn7 transposon in the Bac to Bac system is replaced from the original polh site to the new insertion site, the odv-e56 locus, the resulting BEV can highly express exogenous genes. It is particularly noteworthy that the stability of the BEV during continuous passage is significantly enhanced (Pijlman et al., J Gen Virol, 2003, 84: 2669-78). In addition, studies have shown that the traditional shuttle plasmid-based baculovirus system, which simultaneously accommodates the Rep gene, Cap gene, and ITR core expression elements on the shuttle plasmid, has poor stability. The highly integrated recombinant baculovirus BEV can only be stably propagated for four generations. After the fifth generation, the yield of rAAV prepared by BEV will be significantly reduced (see Yang et al., 2018, Mol Ther Methods Clin Dev. 2018 Jul 4; 10:38-47.).

[0005] In view of the above background, in order to achieve long-term stable propagation of inserted exogenous genes, it is still necessary to screen new effective insertion sites in the BEV genome. Summary of the Invention

[0006] Based on this, one or more embodiments of the present application provide a nucleic acid molecule, a recombinant baculovirus containing the same, and applications thereof. The technical solution includes:

[0007] One or more embodiments of the present application provide a nucleic acid molecule, comprising: a nucleic acid fragment 1, a nucleic acid fragment 2, and an exogenous gene expression frame for expressing an exogenous fragment located between the nucleic acid fragment 1 and the nucleic acid fragment 2;

[0008] The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair;

[0009] The nucleic acid fragment 1 and the nucleic acid fragment 2 are connected to a non-coding region, the 5' end of the non-coding region is taa and the 3' end is tta, and the exogenous fragment is inserted between taa and tta.

[0010] In some embodiments of the present application, the sequence of the non-coding region is taatta, and the exogenous fragment is inserted between taa and tta.

[0011] In some embodiments of the present application, the length of the sequence of the non-coding region is 7 bp-200 bp.

[0012] In some embodiments of the present application, the tail-to-tail gene pair is from a baculovirus.

[0013] In some embodiments of the present application, the tail-to-tail gene pair is derived from any of the following baculoviruses:

[0014] Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudomonas aeruginosa multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus, and Spodoptera litura nuclear polyhedrosis virus.

[0015] In some embodiments of the present application, the tail-to-tail gene pair is from Autographa californica nuclear polyhedrosis virus.

[0016] In some embodiments of the present application, the tail-to-tail gene pairs are both baculovirus conserved genes.

[0017] In some embodiments of the present application, the exogenous fragment includes one or more of a selection marker gene and a target gene.

[0018] In some embodiments of the present application, the target gene includes AAV packaging essential elements, and the AAV packaging essential elements include one or more of the Cap gene, the Rep gene, and the ITR gene;

[0019] In some embodiments of the present application, a GOI is inserted between the left ITR segment and the right ITR segment of the ITR gene.

[0020] In some embodiments of the present application, the exogenous gene expression cassette includes a promoter that regulates the selection marker gene, including a baculovirus very early promoter.

[0021] In some embodiments of the present application, the exogenous gene expression cassette includes a promoter that regulates the target gene, including a P10 promoter or a PH promoter.

[0022] In some embodiments of the present application, the selection marker gene includes one or more of a luciferase gene, a neomycin resistance gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, and a tryptophan synthetase gene.

[0023] In some embodiments of the present application, the selection marker gene is a luciferase gene.

[0024] In some embodiments of the present application, the target gene encodes one or more of an antibody, a polypeptide, an enzyme, a hormone, a growth factor, and a receptor.

[0025] In some embodiments of the present application, the tail-to-tail gene pair includes any one of the following gene pairs:

[0026] Gene pair 1 consists of the lef4 gene and the orf91 gene, and the corresponding insertion site is denoted as the OB1 site;

[0027] Gene pair 2 is the p15 gene and the cg30 gene, and the corresponding insertion site is denoted as the OB2 site; and,

[0028] Gene pair 3 is the env-prot gene and the pkip gene, and the corresponding insertion site is recorded as the OB3 site. In some embodiments of the present application, the sequence of the non-coding region includes the sequence shown in SEQ ID NO.1.

[0029] In some embodiments of the present application, the sequence of the nucleic acid molecule is as shown at 2779bp to 4912bp in SEQ ID NO.44, as shown at 2779bp to 11984bp in SEQ ID NO.46, as shown at 2779bp to 8988bp in SEQ ID NO.47, as shown at 2903bp to 8875bp in SEQ ID NO.48, as shown at 2861bp to 8881bp in SEQ ID NO.49, as shown at 749bp to 4910bp in SEQ ID NO.50, as shown at 749bp to 4776bp in SEQ ID NO.52, or as shown at 2903bp to 6930bp in SEQ ID NO.53.

[0030] One or more embodiments of the present application further provide a recombinant plasmid, which includes the nucleic acid molecule.

[0031] In some embodiments of the present application, the recombinant plasmid includes a shuttle plasmid.

[0032] In some embodiments of the present application, the recombinant plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.

[0033] One or more embodiments of the present application further provide a recombinant baculovirus, the genome of which includes the nucleic acid molecule.

[0034] In some embodiments of the present application, the recombinant baculovirus includes Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudomonas aeruginosa multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus, or Spodoptera litura nuclear polyhedrosis virus.

[0035] In some embodiments of the present application, the genome has a deletion of one or more of the Chia gene and the Cath gene.

[0036] In some embodiments of the present application, the exogenous fragments defined above are inserted into other gene loci of the genome of the recombinant baculovirus.

[0037] In some embodiments of the present application, the selection marker gene is inserted into any one of the OB1 site, the OB2 site, and the OB3 site.

[0038] One or more embodiments of the present application further provide a method for constructing the recombinant baculovirus, the method comprising the following steps:

[0039] causing homologous recombination between the donor plasmid and the baculovirus genome to construct a recombinant baculovirus;

[0040] The donor plasmid includes the nucleic acid molecule.

[0041] In some embodiments of the present application, the recombinase used in homologous recombination includes RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.

[0042] In some embodiments of the present application, the donor plasmid comprises a shuttle plasmid.

[0043] In some embodiments of the present application, the donor plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.

[0044] One or more embodiments of the present application also provide an adeno-associated virus packaging vector system, which includes AAV packaging essential elements, wherein the AAV packaging essential elements include one or more of the Cap gene, the Rep gene and the ITR gene; the AAV packaging essential elements are located in the same or different nucleic acid molecules.

[0045] In some embodiments of the present application, a GOI is inserted between the left ITR segment and the right ITR segment of the ITR gene.

[0046] One or more embodiments of the present application further provide a method for producing an expression product of an exogenous fragment, the method comprising the following steps:

[0047] The host cells are infected with the recombinant baculovirus and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.

[0048] In some embodiments of the present application, the host cell comprises an insect cell line.

[0049] In some embodiments of the present application, the insect cell line comprises a Lepidoptera insect cell line.

[0050] In some embodiments of the present application, the lepidopteran insect cell line includes a Spodoptera frugiperda cell line, a Bombyx mori cell line or a Trichoplusia ni cell line.

[0051] In some embodiments of the present application, the lepidopteran insect cell line includes an ovarian tissue cell line or a fat body cell line.

[0052] In some embodiments of the present application, the production method further comprises the step of detecting the titer of the obtained recombinant baculovirus.

[0053] In some embodiments of the present application, the titer of the obtained recombinant baculovirus is detected using a standard curve method, comprising the following steps:

[0054] Providing a standard curve, which reflects the linear relationship between the luciferase activity value and the virus titer value; and,

[0055] detecting the activity of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting the activity into the standard curve, and calculating the viral titer of the recombinant baculovirus to be tested;

[0056] The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control.

[0057] One or more embodiments of the present application also provide a method for producing a recombinant adeno-associated virus or a GOI expression product, wherein the production method uses the adeno-associated virus packaging vector system.

[0058] Compared with traditional technologies, the advantages of this application include:

[0059] The present application discovered new insertion sites for exogenous fragments on the baculovirus genome. Insertion of exogenous fragments at these insertion sites does not affect baculovirus replication and is stable in propagation, providing new options for effective insertion into the BEV genome in the baculovirus expression system. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more fully understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for describing the embodiments. Obviously, the drawings described below are only some embodiments of the present application. Those skilled in the art can also derive other drawings based on these drawings without inventive effort.

[0061] Figure 1 Schematic diagram of the recombinant baculovirus genome in the examples of this application; wherein: the left side is a schematic diagram of the AcMNPV recombinant bacmid genome, the baculovirus AcMNPV genome is a double-stranded circular DNA with a total length of 133,894 bp;

[0062] Figure 2 This is the electrophoresis diagram of the products identified by PCR in the pKD46 / DH10Bac competent cells of Example 1;

[0063] Figure 3 This is the electrophoresis diagram of PCR identification of ΔCC-DH10Bac competent cells in Example 1;

[0064] Figure 4 This is the electrophoresis diagram of PCR identification of pKD46 / ΔCC-DH10Bac competent cells in Example 1;

[0065] Figure 5 Schematic diagram of the genome of R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} constructed in Example 1;

[0066] Figure 6 Schematic diagram of the genome of R0330{rBEV-8KC-EGFP(OB1)} constructed in Example 2;

[0067] Figure 7 Schematic diagram of the genome of R0331{rBEV-8KC(OB1)-EGFP(Tn7)} constructed in Example 4;

[0068] Figure 8 Schematic diagram of the genome of R0332 {rBEV-8KC (OB1)} constructed in Example 5;

[0069] Figure 9 Schematic diagram of the genome of R0004{rBEV-EGFP(Tn7)} constructed in Example 6;

[0070] Figure 10 Schematic diagram of the genome of R0333{rBEV-8KC(OB2)} constructed in Example 7;

[0071] Figure 11 Schematic diagram of the genome of R0334 {rBEV-8KC (OB2)-EGFP (Tn7)} constructed in Example 8;

[0072] Figure 12 Schematic diagram of the genome of R0335{rBEV-8KC(OB3)} constructed in Example 9;

[0073] Figure 13 Schematic diagram of the genome of R0336{rBEV-ITR-EGFP(OB3)} constructed in Example 10;

[0074] Figure 14 Schematic diagram of the genome of R0337 {rBEV-8KC (OB1)-ITR-EGFP (OB3)} constructed in Example 11;

[0075] Figure 15 Fluorescent photographs of each generation of R0330{rBEV-8KC-EGFP(OB1)} in Example 2, R0336{rBEV-ITR-EGFP(OB3)} in Example 10, and R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)} in Example 11 expanded to P7 at fixed inoculation starting density and inoculation MOI;

[0076] Figure 16 For the correlation analysis of the recombinant baculovirus luciferase activity and titer in Example 13, the standard curve formed by the log value of the titer of the standard and the RLU value, R 2=0.9845;

[0077] Figure 17 These are the staining results of the purified finished viruses of each recombinant baculovirus system model in Example 14. Lane 1 is R0329-AAV8-EGFP in Example 1, lane 2 is R0330-AAV8-EGFP in Example 2, lane 3 is R0331-AAV8-EGFP in Example 4, lane 5 is R0334-AAV8-EGFP in Example 8, lane 6 is R0335-AAV8-EGFP in Example 9, and lane 6 is R0336-AAV8-EGFP in Example 10. The titer of the finished virus purified from the initial mixed solution of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 is low, and only faint shadows can be seen for VP1 and VP2;

[0078] Figure 18 These are the staining results of the purified finished viruses in Example 3. Lane 1 is R0338-AAV9-EGFP, lane 2 is R0339-AAV5-EGFP, and lane 3 is R0340-AAV2-EGFP. The titer of the finished virus purified from the initial mixture of R0338-AAV9-EGFP is low, and VP1 / VP2 is not obvious. DETAILED DESCRIPTION

[0079] Below in conjunction with accompanying drawing, embodiment and example, the application is described in further detail.It should be understood that these embodiment and example are only used to illustrate the application and are not used to limit the scope of the application, and the purpose of providing these embodiment and example is to make the understanding of the disclosure of the application more thorough and comprehensive.It should also be understood that the application can be implemented in many different forms and is not limited to the embodiment and example described herein. Those skilled in the art can make various changes or modifications without violating the connotation of the application, and the equivalent form obtained also falls within the protection scope of the application.In addition, in the description below, a large amount of specific details are given in order to provide a more complete understanding of the application.It should be understood that the application can be implemented without one or more of these details.

[0080] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing embodiments and examples only and are not intended to limit this application.

[0081] the term

[0082] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0083] The terms "and / or", "or / and", and "and / or" used herein include any one of two or more related listed items, and also include any and all combinations of the related listed items, wherein the arbitrary and all combinations include any combination of two related listed items, any more related listed items, or all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions connected by "logical and" and also undoubtedly includes technical solutions connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution of all being connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution of all being connected by "logical AND").

[0084] In this application, "plurality", "multiple", "multiple times", "multiples", etc., unless otherwise specified, refer to a quantity greater than or equal to 2. For example, "one or more" means one or more than or equal to two.

[0085] As used herein, "combination thereof", "any combination thereof", "any combination thereof" and the like include all suitable combinations of any two or more of the listed items.

[0086] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc. shall be based on the ability to implement the technical solution of this application, solve the technical problems of this application, and achieve the expected technical effects of this application.

[0087] Herein, "preferred", "better", "more preferred" and "suitable" are merely used to describe implementation methods or examples with better effects. It should be understood that they do not constitute limitations on the scope of protection of this application.

[0088] In this application, "further", "further", "particularly" and the like are used for descriptive purposes to indicate differences in content, but should not be understood as limiting the scope of protection of this application.

[0089] In this application, the terms "optionally," "optional," and "optional" mean optional or dispensable, i.e., they refer to either option being selected from two parallel options: "with" or "without." If a technical solution contains multiple "optional" clauses, each "optional" clause is independent unless otherwise specified and there are no contradictions or constraints.

[0090] In this application, the terms "first," "second," "third," "fourth," etc. in "the first aspect," "the second aspect," "the third aspect," "the fourth aspect," etc. are used for descriptive purposes only and should not be understood as indicating or implying relative importance or quantity, nor should they be understood as implicitly indicating the importance or quantity of the indicated technical features. Furthermore, "first," "second," "third," "fourth," etc. serve only as non-exhaustive enumeration and description, and should be understood not to constitute a closed-ended limitation on quantity.

[0091] In this application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0092] In this application, when referring to a numerical interval (i.e., a numerical range), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval and includes the two numerical endpoints of the numerical range (i.e., the minimum and maximum values), as well as each numerical value between the two numerical endpoints. Unless otherwise specified, when a numerical interval refers only to integers within the numerical interval, it includes the two endpoint integers of the numerical range, as well as each integer between the two endpoints. In this article, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.

[0093] Unless otherwise specified, the temperature parameters in this application allow for both constant temperature treatment and temperature fluctuations within a certain temperature range. It should be understood that the constant temperature treatment allows for temperature fluctuations within the accuracy range of instrument control. Fluctuations within ranges such as ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are permitted.

[0094] In this application, % (w / w) and wt% both refer to weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass volume percentage.

[0095] All documents mentioned in this application are cited as references in this application, just as each document is cited as reference separately. Unless they conflict with the application purpose and / or technical solution of this application, the cited documents involved in this application are cited in their entirety and for all purposes. When cited documents are involved in this application, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When cited documents are involved in this application, the examples and preferred embodiments of the cited relevant technical features may also be incorporated into this application as references, but are limited to the ability to implement this application. It should be understood that when the cited content conflicts with the description in this application, the present application shall prevail or be adaptively amended according to the description in this application.

[0096] A locus (also known as a locus or loci) is the position on a chromosome occupied by a gene. At the molecular level, it is a DNA segment with a heritable effect. A locus can be a gene, a portion of a gene, or a DNA segment with a regulatory effect. A locus differs from a site, which is the location of a mutation within a cistron and can be as small as a single nucleotide pair.

[0097] Infectious titer refers to the concentration of viral particles capable of transducing cells. Infectious titer is typically quantified using cell transduction assays. Studies have shown that the ratio of rAAV physical titer to infectious titer is approximately 50:1 (Zeltner et al., 2010).

[0098] TCID50, half tissue culture infectious dose, also known as 50% tissue cell infection dose, refers to the amount of virus required to cause cytopathic effect or death (CPE) of half of the cells in the culture plate wells or test tubes, and is used to characterize the titer of the virus.

[0099] A tail-to-tail gene pair refers to two adjacent genes within a genomic region that are located on two different strands of DNA and are transcribed in opposite directions.

[0100] The gene expression box (GEB) is a biological concept that contains the DNA sequences required for gene expression for a specific purpose. This box generally consists of the following four parts: (1) Promoter: The protein-coding region responsible for initiating gene transcription. (2) Codon-optimized coding sequence: The information that guides protein synthesis. (3) Terminator: The region that ends gene transcription. (4) Possible regulatory sequences: Other regulatory elements used to adjust the intensity of gene expression.

[0101] GOI is the abbreviation of Gene of Interest.

[0102] The first aspect of the embodiments of the present application

[0103] A nucleic acid molecule, comprising: a nucleic acid fragment 1, a nucleic acid fragment 2, and an exogenous gene expression frame located between the nucleic acid fragment 1 and the nucleic acid fragment 2 for expressing an exogenous fragment;

[0104] The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair;

[0105] The nucleic acid fragment 1 and the nucleic acid fragment 2 are connected to a non-coding region, the 5' end of the non-coding region is taa and the 3' end is tta, and the exogenous fragment is inserted between taa and tta.

[0106] In some embodiments, the sequence of the non-coding region is taatta. In other embodiments, the length of the sequence of the non-coding region is 7 bp-200 bp, for example, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 185, 190, 195, 200 bp.

[0107] Inserting exogenous fragments into nucleic acid molecules at sites described in the examples of this application does not affect baculovirus replication and provides stable passage, and can achieve higher compatibility. For example, for recombinant competent cells with inserted AAV expression cassettes, it is only necessary to construct the target gene using a traditional Tn7 recombination shuttle plasmid, perform Tn7 recombination, and obtain a recombinant bacmid. Transfection of host cells can achieve the production of recombinant baculovirus packaged with the AAV.

[0108] In some embodiments, the tail-to-tail gene pair is derived from a baculovirus. The baculovirus includes, but is not limited to, Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudomonas aeruginosa multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus, and Spodoptera litura nuclear polyhedrosis virus. The following examples of the present application illustrate the technical solutions of the present application using the tail-to-tail gene pair derived from Autographa californica nuclear polyhedrosis virus as an example, but it should be understood that the present application is not limited thereto.

[0109] In some embodiments, the exogenous segment includes one or more of a selectable marker gene and a target gene. The present application does not specifically limit the type of target gene, including but not limited to AAV packaging essential elements. The AAV packaging essential elements include one or more of a Cap gene, a Rep gene, and an ITR gene. The present application does not particularly limit the serotype of AAV packaged by the essential AAV packaging elements, such as the 13 different serotypes of AAV in primates (i.e., AAV1-AAV13) and related recombinant AVVs (e.g., rAAV2 / 1, rAAV2 / 2, rAAV2 / 3, rAAV2 / 3, rAAV2 / 4, rAAV2 / 5, rAAV2 / 6, rAAV2 / 7, rAAV2 / 8, rAAV2 / 9, rAAV2-retro, AAV-PHP.eB, AAV-PHP.S, AAV-PAN, AAV-LUNG, AAV-DJ, AAV-7m8, AAV-ShH10Y, AAV-Rh10, AAV-Anc80L65, AAV-SCH9). Alternatively, the gene sequence of the Cap gene is a Cap8 sequence that has been codon-optimized based on ribosome leak scanning, further optionally a sequence as shown in SEQ ID No. 2. It is understood that the sequence of the Cap gene is not limited to the Cap8 sequence, and for example, it can also be the sequence of Cap9 contained in SEQ ID NO. 54, the sequence of Cap5 contained in SEQ ID NO. 55, or the sequence of Cap2 contained in SEQ ID NO. 56. Alternatively, the gene sequence of the Rep gene is a Rep2 sequence that has been codon-optimized based on ribosome leak scanning, further optionally a sequence as shown in SEQ ID No. 3. It is understood that the sequence of the Rep gene is not limited to the Rep2 sequence. Alternatively, the ITR gene has the sequences shown in SEQ ID No. 4 (R-ITR) and SEQ ID No. 5 (L-ITR).

[0110] In some embodiments, a GOI is inserted between the left ITR segment (L-ITR) and the right ITR segment (R-ITR) of the ITR gene. The present application does not specifically limit the type of GOI, and it can be any gene of interest to those skilled in the art, including but not limited to genes encoding biologically active proteins (e.g., the EGFP gene shown in SEQ ID No. 6).

[0111] It is understood that in order to achieve the expression of the selection marker gene and / or target gene in the exogenous fragment, the exogenous fragment should contain the complete expression cassette of the selection marker gene and / or target gene. In some embodiments, the exogenous gene expression cassette includes a promoter that regulates the selection marker gene in the expression frame, including a baculovirus very early promoter, which is conducive to the rapid visualization of the infectious titer detection of the recombinant baculovirus containing the nucleic acid molecule. In some embodiments, the exogenous gene expression cassette includes a promoter that regulates the target gene in the expression frame, including a P10 promoter or a PH promoter, for example, the AAV packaging essential elements are located downstream of the promoter and are regulated by the promoter.

[0112] The present application does not particularly limit the selectable marker gene, including but not limited to luciferase gene, neomycin resistance gene, hygromycin phosphotransferase gene, dihydrofolate reductase gene, thymidine kinase gene, glutamine synthetase gene, asparagine synthetase gene, tryptophan synthetase gene, histidinol dehydrogenase gene, aminoglycoside phosphotransferase gene, and tryptophan synthetase gene. The following examples of the present application use luciferase gene as an example to illustrate the technical solution of the present application. It should be understood that the present application is not limited thereto.

[0113] The present application does not impose any particular limitation on the target gene, including but not limited to genes encoding one or more of antibodies, polypeptides, enzymes, hormones, growth factors and protein receptors.

[0114] It will be appreciated that, to achieve homologous recombination, the nucleic acid molecule may contain homology arms recognized by a recombinase, such as RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase, or FLP recombinase, and the sequences of the homology arms may be, for example, LoxP sequence, LoxPL3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1attP sequence, Bxb1attB sequence, attP sequence, attB, attL, and attR sequence.

[0115] In some embodiments, the tail-to-tail gene pair comprises any one of the following gene pairs:

[0116] Gene pair 1 consists of the lef4 gene and the orf91 gene, and the corresponding insertion site is denoted as the OB1 site;

[0117] Gene pair 2 is the p15 gene and the cg30 gene, and the corresponding insertion site is denoted as the OB2 site; and,

[0118] Gene pair 3 is the env-prot gene and the pkip gene, and the corresponding insertion site is denoted as the OB3 site.

[0119] In some embodiments, the sequence of the non-coding region comprises the sequence shown in SEQ ID NO.1.

[0120] Taking the AcMNPV genome as an example: the lef4 gene and the orf91 gene are a tail-to-tail gene pair, and there is a reverse overlapping stop codon ttaa between the two. After changing ttaa to taatta to form a reverse-connected stop codon, the exogenous fragment is inserted between taa and tta (i.e., between 77990bp and 77991bp, corresponding to the OB1 site); the p15 gene and the cg30 gene are a tail-to-tail gene pair, and there is a non-coding region with the sequence of taatta between the two. It is a reverse-connected stop codon between the two, and the exogenous fragment can be directly inserted between taa and tta (i.e., between 74736bp and 74737bp, corresponding to the OB2 site); there is a 48bp non-coding region as shown in SEQ ID NO.1 between the env-prot gene and the pkip gene. The exogenous fragment can be inserted at any site in the 48bp non-coding region, or the 48bp non-coding region can be knocked out and the exogenous fragment can be inserted directly between the env-prot gene and the pkip gene.

[0121] In some embodiments, the sequence of the nucleic acid molecule is as shown at 2779bp to 4912bp in SEQ ID NO.44, as shown at 2779bp to 11984bp in SEQ ID NO.46, as shown at 2779bp to 8988bp in SEQ ID NO.47, as shown at 2903bp to 8875bp in SEQ ID NO.48, as shown at 2861bp to 8881bp in SEQ ID NO.49, as shown at 749bp to 4910bp in SEQ ID NO.50, as shown at 749bp to 4776bp in SEQ ID NO.52, or as shown at 2903bp to 6930bp in SEQ ID NO.53.

[0122] The second aspect of the embodiment of the present application

[0123] A recombinant plasmid comprising the nucleic acid molecule.

[0124] In some embodiments, the recombinant plasmid comprises a shuttle plasmid. Further, the recombinant plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.

[0125] The third aspect of the embodiments of the present application

[0126] A recombinant baculovirus, wherein the genome of the recombinant baculovirus comprises the nucleic acid molecule.

[0127] The present application does not particularly limit the recombinant baculovirus, including but not limited to Autographa californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudomonas aeruginosa multinucleocapsid nuclear polyhedrosis virus, Gypsy moth multinucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multinucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus or Spodoptera litura nuclear polyhedrosis virus. The following examples of the present application are explained using Autographa californica nuclear polyhedrosis virus as an example to illustrate the technical solutions of the present application, but it should be understood that the present application is not limited thereto. Recombinant baculovirus (BEV) has the following advantages as an exogenous gene expression vector: the baculovirus genome is relatively small and easy to operate, the exogenous gene fragments that can be accommodated are large, and the safety is high. Currently, the most widely used recombinant baculovirus (BEV) is based on the genome of Autographa californica nuclear polyhedrosis virus (AcMNPV). The AcMNPV genome is a double-stranded circular DNA with a total length of 133,894 bp. The sequence and map are referenced to GenBank: NC_001623.

[0128] In some embodiments, the recombinant baculovirus genome contains a deletion of one or more of the ChiA gene and the V-Cath gene. The ChiA and V-Cath genes are non-essential genes for baculovirus replication. Removal of the chiA and v-cath encoding genes from the baculovirus genome can improve the secretion efficiency of recombinant proteins and the stability of intracellular proteins, allowing for super-level expression of any protein, including secretory proteins, cell membrane proteins, or proteins that are particularly susceptible to degradation.

[0129] In some embodiments, the other loci of the genome of the recombinant baculovirus are inserted with exogenous fragments as defined above.

[0130] The recombinant baculovirus provided by the present application is characterized in that the exogenous fragment is inserted into any one of the OB1 site, OB2 site and OB3 site.

[0131] In some embodiments, in the recombinant baculovirus, the exogenous segment is inserted into the OB1 site. The exogenous segment may include both the selectable marker gene and the target gene, wherein the target gene may include essential AAV packaging elements, including the Cap gene, Rep gene, and ITR gene, such as the technical solution described in Example 2. The exogenous segment may only include the target gene, wherein the target gene may include essential AAV packaging elements, including the Cap gene, Rep gene, and ITR gene, such as the technical solution described in Example 4.

[0132] In some embodiments, in the recombinant baculovirus, the OB2 site is inserted into the exogenous fragment, and the exogenous fragment may only include the target gene, and the target gene may include AAV packaging essential elements, and the AAV packaging essential elements include the Cap gene, Rep gene and ITR gene, such as the technical solution described in Example 6.

[0133] In some embodiments, in the recombinant baculovirus, the exogenous fragment is inserted into the OB3 site. The exogenous fragment may only include the selection marker gene, such as the technical solution described in Example 9.

[0134] In the recombinant baculovirus provided herein, part of the exogenous fragment is inserted into any one of the OB1 site, the OB2 site, and the OB3 site, and part of the fragment is inserted into other loci; optionally, the other loci include the polh gene (taking the parent bacmid bMON14272 as an example, the insertion can be into the attTn7 transposition site of the polh gene, denoted as the Tn7 site).

[0135] In some embodiments, the exogenous segments include a selectable marker gene and a target gene, wherein the target gene includes an essential AAV packaging element, the selectable marker gene is inserted at the OB1 site, and the target gene is inserted at the Tn7 site. Alternatively, a GOI (e.g., an EGFP gene) is inserted between the left and right ITR segments of the ITR gene in the essential AAV packaging element, such as the technical solution described in Example 1.

[0136] In some embodiments, some of the elements necessary for AAV packaging are inserted into any one of the OB1 site, the OB2 site, and the OB3 site, and the remaining elements are inserted into other loci. Optionally, a GOI (e.g., an EGFP gene) is inserted between the left ITR segment and the right ITR segment of the ITR gene in the AAV packaging essential elements. In one embodiment, the ITR gene is inserted into the other loci, and the Cap gene and the Rep gene are inserted into the OB1 site, such as the solution described in Example 3. In another embodiment, the Cap gene and the Rep gene are inserted into the OB2 site, and the ITR gene is inserted into the other loci, such as the technical solution described in Example 7. In yet another embodiment, the Cap gene and the Rep gene are inserted into the OB3 site, and the ITR gene is inserted into the other loci, such as the technical solution described in Example 8.

[0137] The recombinant baculovirus provided herein has exogenous fragments inserted into multiple sites (e.g., two or three) among the OB1, OB2, and OB3 sites. Among the essential AAV packaging elements, the Cap gene, Rep gene, and ITR gene are each inserted into three sites (with no corresponding relationship to the sites), or two of these elements are inserted into one of the three sites, and the remaining element is inserted into one of the remaining sites. For example, the technical solution described in Example 10.

[0138] In some embodiments, the selectable marker gene is inserted into any one of the OB1 site, the OB2 site, and the OB3 site. Inserting the selectable marker gene into the OB1, OB2, or OB3 site can be used for rapid visual detection of the infectious titer of BEV.

[0139] The fourth aspect of the embodiments of the present application

[0140] A method for constructing the recombinant baculovirus, comprising the following steps:

[0141] causing homologous recombination between the donor plasmid and the baculovirus genome to construct a recombinant baculovirus;

[0142] The donor plasmid includes the nucleic acid molecule.

[0143] In some embodiments of the present application, the recombinase used in homologous recombination includes RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.

[0144] In some embodiments of the present application, the donor plasmid comprises a shuttle plasmid.

[0145] In some embodiments of the present application, the donor plasmid is shown as SEQ ID NO.15, SEQ ID NO.44, SEQ ID NO.46, SEQ ID NO.47, SEQ ID NO.48, SEQ ID NO.49, SEQ ID NO.50, SEQ ID NO.52 or SEQ ID NO.53.

[0146] The fifth aspect of the embodiment of the present application

[0147] An adeno-associated virus packaging vector system comprises essential elements for AAV packaging, wherein the essential elements for AAV packaging include one or more of the Cap gene, the Rep gene and the ITR gene; the essential elements for AAV packaging are located in the same or different nucleic acid molecules.

[0148] In some embodiments, a GOI is inserted between the left and right ITR segments of the ITR gene. The present application does not specifically limit the type of GOI, and the GOI may be any gene of interest to those skilled in the art, including but not limited to genes encoding biologically active proteins (e.g., the EGFP gene shown in SEQ ID No. 6).

[0149] The sixth aspect of the embodiments of the present application

[0150] A method for producing an expression product of an exogenous fragment, the production method comprising the following steps:

[0151] The host cells are infected with the recombinant baculovirus and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.

[0152] In the application examples, the host cell includes an insect cell line. The insect cell line includes, but is not limited to, a Lepidoptera insect cell line. The Lepidoptera insect cell line includes, but is not limited to, a Spodoptera frugiperda cell line, a Bombyx mori cell line, or a Trichoplusia ni cell line. The Lepidoptera insect cell line includes, but is not limited to, an ovarian tissue cell line or a fat body cell line. The most widely used insect cell lines are the Trichoplusia frugiperda ovarian cell line (Sf21), Sf9 cells cloned from Sf21 cells, and the H5 (High Five) cell line.

[0153] In some embodiments, the production method further comprises the step of detecting the titer of the obtained recombinant baculovirus.

[0154] In some embodiments, the titer of the obtained recombinant baculovirus is detected using a standard curve method, comprising the following steps:

[0155] Providing a standard curve, which reflects the linear relationship between the luciferase activity value and the virus titer value; and,

[0156] detecting the activity of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting the activity into the standard curve, and calculating the viral titer of the recombinant baculovirus to be tested;

[0157] The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control.

[0158] The seventh aspect of the embodiment of the present application

[0159] One or more embodiments of the present application also provide a method for producing a recombinant adeno-associated virus or a GOI expression product, wherein the production method uses the adeno-associated virus packaging vector system.

[0160] The embodiments of the present application will be described in detail below with reference to the examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manuals or conventional conditions in this area, or according to the conditions recommended by the manufacturer, or with reference to experimental methods known in the art.

[0161] In the following specific examples, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument testing accuracy or operational accuracy are allowed.

[0162] Combine Figure 1 In this application, the genome sequence of baculovirus AcMNPV (Autographa californica nuclear polyhedrosis virus) was analyzed, and multiple baculovirus conserved gene loci were selected for testing. Finally, three sites were optimally designed: the OB1 site is the reverse overlapping stop codon ttaa located at 77987-77990 bp between the C-termini of Ac-lef-4 and Ac-orf-91. After ttaa is changed to taatta to form a reverse-connected stop codon, the reverse-connected stop codon junction site is located at 77990 bp; the OB2 site is the reverse-connected stop codon junction site located at 74736 bp between the C-termini of the conserved gene loci Ac-p15 and Ac-cg30; and the OB3 site is the 48 bp non-coding region located at 20586-20633 bp between the C-termini of the conserved gene loci Ac-env-prot and Ac-pkip (SEQ ID NO. 1).

[0163] Example 1. Obtaining a recombinant baculovirus expressing the reporter gene Luciferase and Tn7 recombinant 8KC-EGFP at the OB1 insertion site, R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}

[0164] 1 Construction of the Gluc expression cassette baculovirus vector GLuc(OB1)-ΔCC-DH10Bac

[0165] 1.1 Preparation of pKD46 / ΔCC-DH10Bac competent cells

[0166] (1) Preparation of pKD46 / DH10Bac competent cells

[0167] The pKD46 plasmid is a temperature-sensitive low-copy plasmid. At 30°C, the addition of arabinose to the culture medium of cells transfected with the pKD46 plasmid can induce the expression of three proteins (i.e., Red recombinases), Exo, Beta, and Gam. This allows efficient and specific recombination of exogenous genes carrying homology arms with the bacmid genome in bacteria (see Doublet et al., 2008, J Microbiol Methods., 75(2):359-61).

[0168] In this application, pKD46 was transformed into DH10Bac competent cells, cultured at 30°C throughout the entire process, and after screening and identification, the competent cells were shaken. After induction for 2 hours by adding 100 mM (final concentration) L-arabinose when the OD600 was 0.2, pKD46 / DH10Bac competent cells were prepared.

[0169] Primers for identifying the Bet gene of pKD46: Bet-F sequence is 5'-atgagtactgcactcgcaa-3' (SEQ ID NO. 20), and Bet-R sequence is 5'-tgctctgcggctttctgtt-3' (SEQ ID NO. 21); amplified fragment size: 768 bp; if a 768 bp amplified fragment is detected, the bacteria are considered positive;

[0170] Primers for identifying the araC gene of pKD46: the sequence of araC-F is 5'-ttatgacaacttgacggctaca-3' (SEQ ID NO. 22), and the sequence of araC-R is 5'-atggctgaagcgcaaaatga-3' (SEQ ID NO. 23); amplified fragment size: 879 bp; if an 879 bp amplified fragment is detected, the bacteria are judged to be positive.

[0171] The electrophoresis diagram of PCR identification of pKD46 / DH10Bac competent cells is shown in the figure below. Figure 2. Figure 2 Middle: Marker is 2000bp. Lanes 1, 2, 3, and 4 are electrophoresis bands of PCR products using primers identifying the Bet gene of pKD46 from strain selections 1 to 4. The target band is 768bp in size, indicating that the tested strain is positive. Lanes 5, 6, 7, and 8 are electrophoresis bands of PCR products using primers identifying the araC gene of pKD46 from strain selections 1 to 4. The target band is 879bp in size, indicating that the tested strain is positive. Strain selection 3 is a target positive strain with pKD46 / DH10Bac that meets the identification requirements.

[0172] (2) Preparation of ΔCC-DH10Bac competent cells

[0173] This application knocks out the ChiA and V-Cath genes of the baculovirus (ChiA and V-Cath genes are non-essential genes for baculovirus replication. Removal of the chiA and v-cath encoding genes in the baculovirus genome can improve the secretion efficiency of recombinant proteins and the stability of intracellular proteins, and can enable super-level expression of any protein, including secretory proteins, cell membrane proteins, or proteins that are particularly susceptible to degradation):

[0174] The DH10Bac competent cell culture was shaken and the AcMNPV genomic bacmid bMON14272 was extracted. Using the AcMNPV genomic bacmid bMON14272 as a template, primers HAL(lef7)-F (SEQ ID NO. 24): 5'-gggtgtacaggtaacggccaatt-3' and HAL(lef7)-R (SEQ ID NO. 25): 5'-TCCCCCCGGGaagcaatatattgagtatcaTTTTAG-3' were designed to amplify the fragment HAL(lef7) (420 bp) (sequence shown in SEQ ID NO. 7). Using the AcMNPV genomic bacmid bMON14272 as a template, primers HAR(GP64)-F (SEQ ID NO. 26): 5'-ACATGcatgctctcaacacactcgctatttgga-3' and HAR(GP64)-R (SEQ ID NO. 27): 5'-ACATGcatgctctcaacacactcgctatttgga-3' were designed to amplify the fragment HAL(lef7) (420 bp) (sequence shown in SEQ ID NO. 7). NO.27): 5'-AGCTTTGTTTAAACtggagaacaccaagtttg-3', amplified fragment HAR (GP64) (430 bp) (sequence shown in SEQ ID NO.8);

[0175] To facilitate the screening of recombinants, a chloramphenicol (CmR) resistance gene flanked by Frt fragments was introduced. Primers Nhe IF (SEQ ID NO. 28): 5'-ctaGCTAGCgtgtaggctggag-3' and HindIII-R (SEQ ID NO. 29): 5'-cccAAGCTTatgggaattagccatg-3' were designed to amplify the fragment P1-FRT-CmR-P2 (1053 bp) from the pKD3 plasmid (sequence shown in SEQ ID NO. 9).

[0176] HAL (lef7) (420 bp), HAR (GP64) (430 bp) and P1-FRT-CmR-P2 (1053 bp) were cloned on the vector plasmid pQB1064 using the molecular cloning recombination method of restriction enzyme cutting sites.

[0177] pQB1064-HAL(lef7)-P1-FRT-CmR-P2-HAR(GP64) plasmid,

[0178] After linearization of the pQB1064-HAL(lef7)-P1-FRT-CmR-P2-HAR(GP64) plasmid, DNA fragments were recovered by gel recovery.

[0179] HAL (lef7) -P1-FRT-CmR-P2-HAR (GP64), the DNA fragment was transformed into pKD46 / DH10Bac (pick number 3 in step (1)) competent cells, the Chia and V-Cath genes of the baculovirus were knocked out, and the monoclonal bacterial liquid of pKD46 / CmR-ΔCC-DH10Bac was obtained by resistance (chloramphenicol resistance) plate screening. After culturing at 42 ° C to eliminate the pKD46 plasmid, CmR-ΔCC-DH10Bac competent cells were prepared by resistance plate screening. The pCP20 plasmid was transformed into CmR-ΔCC-DH10Bac competent cells. After culturing at 42 ° C to eliminate the pCP20 plasmid, the ΔCC-DH10Bac competent cells were prepared by screening and identification.

[0180] ΔCC-DH10Bac identification primers:

[0181] Identification primers for the Bet gene of pKD46: Bet-F (SEQ ID NO. 20): 5'-atgagtactgcactcgcaa-3' and Bet-R (SEQ ID NO. 21): 5'-tgctctgcggctttctgtt-3'; amplified fragment size: 768 bp; if an amplified fragment of 768 bp is detected, the strain is negative;

[0182] The primers for successful homology arm recombination identification were: pCAT-HAL(lef7)-F (SEQ ID NO.30): 5'-cgatcaactttctcgccaac-3' and pCAT-HAR(gp64)-R (SEQ ID NO.31): 5'-gactcgtcgcaatgcata-3'; amplified fragment size: 1347 bp; if an amplified fragment of 1347 bp was detected, the strain was positive; the primers for the pCP20 plasmid FLP-F (SEQ ID NO.32): 5'-CCCTTGCGCTAAAGAAGT-3' and FLP-R (SEQ ID NO.33): 5'-GAGAGCCACATTCATGAG-3'; amplified fragment size: 551 bp; if an amplified fragment of 551 bp was detected, the strain was negative;

[0183] Primers for identifying CmR sequences: pCAT-Chl-F (SEQ ID NO.34): 5'-tgatcggcacgtaagaggtt-3' and pCAT-Chl-R (SEQ ID NO.35): 5'-actggtgaaactcaccca-3'; amplified fragment size: 568 bp; if this amplified fragment is detected, it is a negative strain.

[0184] The electrophoresis diagram of PCR identification of ΔCC-DH10Bac is as follows Figure 3 . Figure 3 In Figure A, the marker is 2000 bp. Lanes 1, 2, 3, 4, and 5 are electrophoretic bands of the PCR products of the identification primers for the Bet protein of pKD46 of the strain picking number 1 to 5. The target band size is 768 bp, indicating negative bacteria. Lanes 6, 7, 8, 9, and 10 are electrophoretic bands of the PCR products of the identification primers pCAT-HAL(lef7)-F and pCAT-HAL(gp64)-R of the strain picking number 1 to 5. The target band size is 1347 bp, indicating positive bacteria. Lanes 11, 12, 13, 14, and 15 are electrophoretic bands of the PCR products of the identification primers for the pCP20 plasmid of the strain picking number 1 to 5. The target band size is 551 bp, indicating negative bacteria. Figure 3 In panel B, the marker is 2000 bp. Lanes 1, 2, 3, 4, and 5 show the electrophoresis bands of the PCR products using the identification primers for the CmR fragment of picks 1 to 5. The target band is 568 bp, indicating negative bacteria. Picks 3 and 4 are target positive strains that meet the identification requirements for ΔCC-DH10Bac.

[0185] (3) Preparation of pKD46 / ΔCC-DH10Bac competent cells

[0186] Transform the pKD46 plasmid into ΔCC-DH10Bac competent cells and culture them at 30°C throughout the entire process. After screening and identification, shake the competent cells. Add 100mM L-arabinose at an OD600 of 0.2 and induce for 2 hours to prepare L-arabinose-induced electroporation competent cells of pKD46 / ΔCC-DH10Bac. Identification primers for pKD46 / ΔCC-DH10Bac:

[0187] The Bet gene of pKD46, Bet-F (SEQ ID NO. 20): 5'-atgagtactgcactcgcaa-3' and Bet-R (SEQ ID NO. 21): 5'-tgctctgcggctttctgtt-3'; amplified fragment size: 768 bp; detection of this amplified fragment indicates a positive bacterium;

[0188] The primers for successful homologous arm recombination identification were pCAT-HAL(lef7)-F (SEQ ID NO.30): 5'-cgatcaactttctcgccaac-3' and pCAT-HAR(gp64)-R (SEQ ID NO.31): 5'-gactcgtcgcaatgcata-3'; the amplified fragment size was 1347 bp; if the amplified fragment was detected, it was judged as a positive bacterium.

[0189] The electrophoresis diagram of PCR identification of pKD46 / ΔCC-DH10Bac is shown in Figure 4 . Figure 4 In Figure A, the lane markers are 2000 bp and 10000 bp respectively. Lanes 1, 2, 3, and 4 are the electrophoresis bands of the PCR products of the Bet gene of pKD46 with identification primers from strains 1 to 4. The target band size is 768 bp, indicating positive bacteria. Figure 4 In Figure B, the marker is 2000bp, and lanes 1, 2, 3, and 4 are the electrophoresis bands of the PCR products of the successful identification primers pCAT-HAL(lef7)-F and pCAT-HAL(gp64)-R for homologous arm recombination of the strains picking numbers 1 to 4. The target band size is 1347bp, indicating positive bacteria; among them, the strains picking numbers 1 and 2 are the target positive strains of pKD46 / ΔCC-DH10Bac that meet the identification requirements.

[0190] 1.2 Preparation of CmR-GLuc(OB1)-ΔCC-DH10Bac competent cells

[0191] Similarly, using the AcMNPV genomic bacmid bMON14272 as a template, primers HAL(lef4)-F (SEQ ID NO. 36): 5'-ccaATGCATtcatacgctatagatccg-3' and HAL(lef4)-R (SEQ ID NO. 37): 5'-tccCCCGGGttaatttggcacgattcg-3' were designed to amplify the fragment HAL(lef4) (420 bp) (sequence shown in SEQ ID NO. 10); using the AcMNPV genomic bacmid bMON14272 as a template, primers HAR(ORF91)-F (SEQ ID NO. 38): 5'-acatGCATGCttaaagcacgttaagcg-3' and HAR(ORF91)-R (SEQ ID NO. 39): 5'-acatGCATGCttaaagcacgttaagcg-3' were designed to amplify the fragment HAL(lef4) (420 bp) (sequence shown in SEQ ID NO. 10). ID NO.39): 5'-agctttGTTTAAACtccaccttctcctat-3', amplified fragment HAR (ORF91) (344 bp) (sequence shown in SEQ ID NO.11);

[0192] In this example, the baculovirus early-to-late ETL promoter was used to regulate the Luciferase reporter gene. The expression cassette containing the SV40pA element was constructed as ETL-Luciferase-SV40pA (sequence shown in SEQ ID NO. 12). Because ETL is an early-to-late promoter, it can initiate Luciferase expression relatively early after BEV infection of host cells. The sequence pETL-GLuc-Dura-SV40pA was synthesized by a biotechnology company.

[0193] HAL (lef4) (420 bp), HAR (ORF91) (344 bp), P1-FRT-CmR-P2 (1053 bp) and the synthetic fragment pETL-GLuc-Dura-SV40pA were cloned into the vector plasmid pQB1064 using the molecular cloning recombination method of restriction enzyme cutting sites to obtain the pQB1064-HAL (lef4) -P1-FRT-CmR-P2-pETL-GLuc-Dura-SV40pA-HAR (ORF91) plasmid (SEQ ID NO. 44, the vector sequence of SEQ ID NO. 44 will clarify the actual sequence and position of the OB1 site GLuc (OB1)). After linearization of the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-HAR(ORF91) plasmid, the DNA fragment HAL(lef4)-P1-FRT-CmR-P2-pETL-GLuc-Dura-SV40Pa-HAR(ORF91) was recovered by gel extraction. This DNA fragment was transformed into an L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac (pKD46 / ΔCC-DH10Bac in the microplate number 1). A single clone of pKD46 / CmR-GLuc(OB1)-ΔCC-DH10Bac was obtained by screening and identification. After incubation at 42°C to eliminate the pKD46 plasmid, CmR-GLuc(OB1)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.

[0194] During the experiment, it was found that after the pCP20 plasmid was transformed into a competent state with a chloramphenicol expression cassette after two knockouts, all the target fragments of the knockout insertion were identified as lost. The reason is that after the knockout using RED recombination, an FRT target site will be left on one side. After two knockouts, two FRT target sites will be left, which will form unidirectional complementation and form a large-fragment knockout, thus retaining the chloramphenicol resistance expression cassette left by the knockout.

[0195] 2 Obtain recombinant baculovirus R0329 {rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} through Tn7 recombination

[0196] A cloning vector for co-expression of the packaging elements of adeno-associated virus AAV8 was constructed using the AAV8-EGFP packaging element expression cassette (sequence shown in SEQ ID NO. 13) consisting of Cap8 (sequence shown in SEQ ID NO. 2), Rep2 (sequence shown in SEQ ID NO. 3) and ITR-EGFP (sequence shown in SEQ ID NO. 6) disclosed in this application.

[0197] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45, the vector sequence of SEQ ID NO.45 will clarify the actual sequence and position of 8KC-EGFP (Tn7) at the Tn7 site). Then, pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR was used to transform the CmR-GLuc(OB1)-ΔCC-DH10Bac competent cells prepared in step 1.2. Recombinant clones were screened by blue-white screening, and recombinant bacmid DNA was extracted by shaking. The bacmid DNA was transfected into the host cell line and cultured for 4 days to obtain recombinant baculovirus.

[0198] R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P0 was transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected, resulting in Sf9 cells obtaining a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0329-AAV8-EGFP after virus collection. The virus was infected as follows Figure 17 Lane 1.

[0199] The genome diagram of R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)} is shown in Figure 5 .

[0200] Example 2. Obtaining a recombinant baculovirus containing an AAV8-EGFP packaging element expression cassette at the OB1 insertion site, R0330 {rBEV-8KC-EGFP (OB1)}

[0201] 1. Preparation of CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac competent cells

[0202] A cloning vector for co-expression of the packaging elements of the adeno-associated virus AAV8 constructed using Example 1

[0203] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was digested and gel-recovered to obtain a linearized DNA fragment of the AAV8-EGFP packaging element expression cassette (sequence shown in SEQ ID NO.13). The HAL (lef4) (420 bp), HAR (ORF91) (344 bp), P1-FRT-CmR-P2 (1053 bp) and AAV8-EGFP packaging element expression cassette (sequence shown in SEQ ID NO.13) were recombined by molecular cloning with restriction enzyme sites. The linearized DNA fragment was cloned into the vector plasmid pQB1064 (SEQ ID NO. 13) to obtain the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) plasmid (SEQ ID NO. 46, the vector sequence of SEQ ID NO. 46 will clarify the actual sequence and position of 8KC-EGFP (OB1) at the OB1 site). The pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) plasmid was linearized and the DNA fragment HAL(lef4)-P1-FRT-CmR-P2-8KC-EGFP-HAR(ORF91) was recovered by gel extraction. This DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the competent cells of CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac were prepared by resistance plate screening.

[0204] 2. Extract the bacmid and transfect the host cells to obtain the recombinant baculovirus R0330{rBEV-8KC-EGFP(OB1)}

[0205] CmR-8KC-EGFP(OB1)-ΔCC-DH10Bac competent cells were shaken, and recombinant bacmid DNA was extracted. The bacmid DNA was transfected into the host cell line and cultured for 4 days to obtain recombinant baculovirus R0330{rBEV-8KC-EGFP(OB1)}#P0. The recombinant baculovirus was transferred into suspension Sf9 cells and cultured for 3 days. The recombinant baculovirus that replicated and proliferated further infected the Sf9 cells, resulting in a higher titer of seed virus. The packaged cell suspension was centrifuged at 3000 rpm for 5 minutes, and the supernatant was aliquoted and stored to obtain the harvested recombinant baculovirus.

[0206] R0330{rBEV-8KC-EGFP(OB1)}#P1, the remaining packaged cell suspension was collected and used to purify the recombinant adeno-associated virus R0330-AAV8-EGFP. The genome diagram of R0330{rBEV-8KC-EGFP(OB1)} is shown in the figure. Figure 6 The fluorescence photos of cells in R0330{rBEV-8KC-EGFP(OB1)}#P1 were expanded to P7 at a fixed inoculation starting density and MOI. Figure 15 As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB1 site remained stable in the P7 generation.

[0207] Example 3. Obtaining recombinant baculoviruses with AAV9-EGFP, AAV5-EGFP, and AAV2-EGFP packaging element expression cassettes loaded in the OB1 insertion site, R0338 {rBEV-9KC-EGFP (OB1)}, R0339 {rBEV-5KC-EGFP (OB1)}, and R0340 {rBEV-2KC-EGFP (OB1)}

[0208] 1. Preparation of CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells

[0209] The synthetic sequences p10-Cap9-PA (SEQ ID NO. 54), p10-Cap5-PA (SEQ ID NO. 55) and p10-Cap2-PA (SEQ ID NO. 56) were sent respectively.

[0210] The pQB1064-HAL (lef4) -P1-FRT-CmR-P2-8KC-EGFP-HAR (ORF91) plasmid (SEQ ID NO. 46) was constructed using Example 1. The Cap8 sequence marked in the SEQ ID NO. 46 sequence was replaced with Cap9, Cap5, and Cap2 through the restriction sites at both ends of each sequence of p10-Cap9-PA (SEQ ID NO. 54), p10-Cap5-PA (SEQ ID NO. 55), and p10-Cap2-PA (SEQ ID NO. 56), to obtain the pQB1064-HAL (lef4) -P1-FRT-CmR-P2-9KC-EGFP-HAR (ORF91) plasmid.

[0211] pQB1064-HAL(lef4)-P1-FRT-CmR-P2-5KC-EGFP-HAR(ORF91) plasmid and

[0212] pQB1064-HAL(lef4)-P1-FRT-CmR-P2-2KC-EGFP-HAR(ORF91) plasmid. After linearization of the above plasmids, the DNA fragments HAL(lef4)-P1-FRT-CmR-P2-9KC-EGFP-HAR(ORF91) were obtained by gel recovery.

[0213] HAL(lef4)-P1-FRT-CmR-P2-5KC-EGFP-HAR(ORF91) and

[0214] HAL(lef4)-P1-FRT-CmR-P2-2KC-EGFP-HAR(ORF91), the above DNA fragments were transformed into the L-arabinose-induced electroporation competent cells of pKD46 / ΔCC-DH10Bac, and the monoclonal bacterial solutions of pKD46 / CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, pKD46 / CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac, and pKD46 / CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac were screened and identified, and after culturing at 42°C to eliminate the pKD46 plasmid, the monoclonal bacterial solutions were prepared by resistance plate screening.

[0215] CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and

[0216] CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells.

[0217] 2. Recombinant baculoviruses R0338{rBEV-9KC-EGFP(OB1)}, R0339{rBEV-5KC-EGFP(OB1)} and R0340{rBEV-2KC-EGFP(OB1)} were obtained by extracting the bacmid and transfecting the host cells.

[0218] CmR-9KC-EGFP(OB1)-ΔCC-DH10Bac, CmR-5KC-EGFP(OB1)-ΔCC-DH10Bac and CmR-2KC-EGFP(OB1)-ΔCC-DH10Bac competent cells were shaken, and recombinant bacmid DNA was extracted respectively. The bacmid DNA was transfected into host cell lines and cultured. After 4 days of culture, recombinant baculovirus R0338{rBEV-9KC-EGFP(OB1)}#P0, R0339{rBEV-5KC-EGFP(OB1)}#P0 and R0340{rBEV-2KC-EGFP(OB1)}#P0 were obtained. They were respectively transferred into suspension Sf9 cells and cultured for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities was further infected to obtain a higher titer of seed virus in Sf9 cells. The packaged part was centrifuged at 3000 rpm for 5 min. The cell suspension was aliquoted and stored as the harvested recombinant baculovirus R0338{rBEV-9KC-EGFP(OB1)}#P1, R0339{rBEV-5KC-EGFP(OB1)}#P1, and R0340{rBEV-2KC-EGFP(OB1)}#P1. The remaining packaged cell suspensions were harvested and used to purify the recombinant adeno-associated viruses R0338-AAV9-EGFP, R0339-AAV5-EGFP, and R0340-AAV2-EGFP. The electrophoresis images were shown in Figure 2. Figure 18 The genome diagrams of R0338, R0339 and R0340 are the same as those of R0330. Figure 6 .

[0219] Example 4. Obtaining a recombinant baculovirus containing an AAV8 packaging element expression cassette and Tn7 recombinant ITR-EGFP at the OB1 insertion site, R0331 {rBEV-8KC (OB1) -EGFP (Tn7)}

[0220] 1. Preparation of CmR-8KC(OB1)-ΔCC-DH10Bac competent cells

[0221] The adeno-associated virus AAV8 packaging element co-expression cloning vector pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was constructed using Example 1. The AAV8 packaging element expression cassette (sequence shown in SEQ ID NO.14) was linearized by enzyme digestion and gel recovery. The HAL (lef4) (420 bp), HAR (ORF91) (344 bp), P1-FRT-CmR-P2 (1053 bp) and AAV8 packaging element expression cassette (sequence shown in SEQ ID NO.14) were recombined by molecular cloning using restriction enzyme sites. The linearized DNA fragment was cloned into the vector plasmid pQB1064 (SEQ ID NO. 14) to obtain the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-HAR(ORF91) plasmid (SEQ ID NO. 47, the vector sequence of SEQ ID NO. 47 will clarify the actual sequence and position of OB1 site 8KC (OB1)). After linearization of the pQB1064-HAL(lef4)-P1-FRT-CmR-P2-8KC-HAR(ORF91) plasmid, the DNA fragment HAL(lef4)-P1-FRT-CmR-P2-8KC-HAR(ORF91) was recovered by gel extraction and transformed into an L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. A monoclonal bacterial solution of pKD46 / CmR-8KC(OB1)-ΔCC-DH10Bac was obtained by screening and identification. After culturing at 42°C to eliminate the pKD46 plasmid, the competent cells of CmR-8KC(OB1)-ΔCC-DH10Bac were prepared by resistance plate screening.

[0222] 2 Obtaining recombinant baculovirus R0331 {rBEV-8KC (OB1)-EGFP (Tn7)} through Tn7 recombination

[0223] A cloning vector for co-expression of the packaging elements of the adeno-associated virus AAV8 constructed using Example 1

[0224] pFastBac1-AAV8-SV40pA-Rep2←Polh..P10→Cap8-HSV-TKpA-ITR-CMV-EGFP-WPRE-hGHpA-ITR (SEQ ID NO.45) was digested and gel-recovered to obtain a linearized DNA fragment of the ITR-EGFP packaging element expression cassette (sequence shown in SEQ ID NO.6), and the cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR (sequence shown in SEQ ID NO.15, the vector sequence of SEQ ID NO.15 will clarify the actual sequence and position of EGFP (Tn7) at the Tn7 site) was constructed. The pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR plasmid was then used to transform CmR-8KC(OB1)-ΔCC-DH10Bac competent cells, and recombinant clones were screened by blue-white screening. The recombinant bacmid DNA was extracted by large shaking, and the bacmid was cloned into the cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR. The DNA was transfected into the host cell line and cultured for 4 days to obtain the recombinant baculovirus R0331{rBEV-8KC(OB1)-EGFP(Tn7)}#P0, which was then transferred into suspension Sf9 cells and cultured for 3 days. The massively replicated and proliferated recombinant baculovirus further infected the Sf9 cells, resulting in a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000rm for 5min, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0331{rBEV-8KC(OB1)-EGFP(Tn7)}#P1. The remaining packaged cell suspension was collected and used to purify the recombinant adeno-associated virus R0331-AAV8-EGFP.

[0225] The genome diagram of R0331{rBEV-8KC(OB1)-EGFP(Tn7)} is shown in Figure 7 .

[0226] Example 5. Obtaining a recombinant baculovirus containing an AAV8 packaging element expression cassette at the OB1 insertion site, R0332 {rBEV-8KC (OB1)}

[0227] Example 4 was used to construct CmR-8KC(OB1)-ΔCC-DH10Bac competent cells. The CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were shaken to extract recombinant bacmid DNA. The bacmid DNA was transfected into a host cell line and cultured for 4 days. Recombinant baculovirus R0332{rBEV-8KC(OB1)}#P0 was obtained and transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells to obtain a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 minutes, and the supernatant was aliquoted and stored to obtain the harvested recombinant baculovirus R0332{rBEV-8KC(OB1)}#P1. The genome schematic diagram of R0332{rBEV-8KC(OB1)} is shown in FIG. Figure 8 .

[0228] Example 6. Obtaining a recombinant baculovirus containing an AAV8 packaging element expression cassette at the OB1 insertion site, R0004 {rBEV-EGFP (Tn7)}

[0229] The cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR (sequence shown in SEQ ID NO. 15) constructed in Example 4 was used to transform the ΔCC-DH10Ba competent cells prepared in Example 1. Recombinant clones were screened by blue-white screening, and recombinant bacmid DNA was extracted by shaking. The bacmid DNA was transfected into the host cell line and cultured for 4 days. Recombinant baculovirus R0004{rBEV-EGFP(Tn7)}#P0 was obtained. The recombinant baculovirus was transferred to suspension Sf9 cells and cultured for 3 days. The recombinant baculovirus that replicated and proliferated further infected the Sf9 cells, resulting in a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the harvested recombinant baculovirus R0004{rBEV-EGFP(Tn7)}#P1. The genome diagram of R0004{rBEV-EGFP(Tn7)} is shown in Figure 9 .

[0230] Example 7. Obtaining a recombinant baculovirus, R0333 {rBEV-8KC (OB2)}, in which the OB2 insertion site is loaded with an AAV8 packaging element expression cassette.

[0231] 1. Preparation of CmR-8KC(OB2)-ΔCC-DH10Bac competent cells

[0232] Similarly, using the AcMNPV genomic bacmid bMON14272 as a template, primers HAL(p15)-F (SEQ ID NO. 40): 5'-ATGCATtaccatcgcatacaac-3' and HAL(p15)-R (SEQ ID NO. 41): 5'-ACTAGTttaactgtttacataac-3' were designed to amplify the fragment HAL(p15) (412 bp) (sequence shown in SEQ ID NO. 16). Using the AcMNPV genomic bacmid bMON14272 as a template, primers HAR(cg30)-F (SEQ ID NO. 42): 5'-Gcatgcttaatctacatttattgtaac-3' and HAR(cg30)-R (SEQ ID NO. 43): 5'-GTTTAAACgaagacaacaacgc-3' were designed to amplify the fragment HAR(cg30) (458 bp) (sequence shown in SEQ ID NO. 17).

[0233] HAL (p15) (412 bp), HAR (cg30) (458 bp), P1-FRT-CmR-P2 (1053 bp), and the AAV8 packaging element expression cassette (sequence shown in SEQ ID NO. 14) were linearized into DNA fragments using a molecular cloning recombination method using restriction enzyme sites. The DNA fragments were cloned into the vector plasmid pQB1064 to obtain the pQB1064-HAL (p15) -P1-FRT-CmR-P2-8KC-HAR (cg30) plasmid (SEQ ID NO. 48, the vector sequence of SEQ ID NO. 48 will clarify the actual sequence and position of the OB2 site 8KC (OB2)). After the pQB1064-HAL (p15) -P1-FRT-CmR-P2-8KC-HAR (ORF91) plasmid was linearized, the DNA fragments were recovered by gel recovery.

[0234] The DNA fragment HAL(p15)-P1-FRT-CmR-P2-8KC-HAR(ORF91) was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac, and the monoclonal bacterial solution of pKD46 / CmR-8KC(OB2)-ΔCC-DH10Bac was obtained by screening and identification. After culturing at 42°C to eliminate the pKD46 plasmid, CmR-8KC(OB2)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.

[0235] 2 Obtain recombinant baculovirus R0333 {rBEV-8KC (OB2)}

[0236] The CmR-8KC(OB2)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0333{rBEV-8KC(OB2)}#P0 was obtained, which was transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells to obtain a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 minutes, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0333{rBEV-8KC(OB2)}#P1. The genome diagram of R0333{rBEV-8KC(OB2)} is shown in the figure. Figure 10 .

[0237] Example 8. Obtaining a recombinant baculovirus containing an AAV8 packaging element expression cassette and Tn7 recombinant ITR-EGFP at the OB2 insertion site, R0334 {rBEV-8KC (OB2) -EGFP (Tn7)}

[0238] The cloning vector pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR constructed in Example 4 (sequence shown in SEQ ID NO. 15, the vector sequence of SEQ ID NO. 15 will clarify the actual sequence and position of EGFP (Tn7) at the Tn7 site. The actual sequence and position of 8KC (OB2) have been clarified in the previous example.) was used to transform the pFastBac1-ITR-CMV-EGFP-WPRE-hGHpA-ITR plasmid into the CmR-8KC (OB2)-ΔCC-DH10Bac competent cells prepared in Example 7. Recombinant clones were screened by blue-white screening, and recombinant bacmid DNA was extracted by shaking. The bacmid DNA was transfected into the host cell line and cultured for 4 days to obtain recombinant baculovirus.

[0239] R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P0 was transferred into suspension Sf9 cells for 3 days. The recombinant baculovirus that replicated and proliferated further infected the Sf9 cells, resulting in a higher titer of seed virus. The partially packaged cell suspension was centrifuged at 3000rpm for 5 minutes, and the supernatant was packaged and stored, which was the harvested recombinant baculovirus R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P1. The remaining packaged cell suspension was used to purify the recombinant adeno-associated virus R0334-AAV8-EGFP after the virus was collected. The genome diagram of R0334{rBEV-8KC(OB2)-EGFP(Tn7)} is shown below. Figure 11 .

[0240] Example 9. Obtaining a recombinant baculovirus loaded with ITR-EGFP at the OB3 insertion site, R0335{rBEV-8KC(OB3)-EGFP(Tn7)}

[0241] 1. Preparation of CmR-8KC(OB3)-ΔCC-DH10Bac competent cells

[0242] Because the terminal sequences of the upstream and downstream homology arms of the OB3 locus have very low GC content, we commissioned a biotechnology company to synthesize the sequence HAL(prot) (478 bp) (sequence shown in SEQ ID NO. 18); and outsourced the synthesis of HAR(pkip) (428 bp) (sequence shown in SEQ ID NO. 19).

[0243] HAL (prot) (478 bp), HAR (pkip) (428 bp), P1-FRT-CmR-P2 (1053 bp), and the AAV8 packaging element expression cassette (sequence shown in SEQ ID NO. 14) were linearized into DNA fragments using a molecular cloning recombination method using restriction enzyme sites. The DNA fragments were cloned into the vector plasmid pQB1064 to obtain the pQB1064-HAL (prot) -P1-FRT-CmR-P2-8KC-HAR (pkip) plasmid (SEQ ID NO. 49, the vector sequence of SEQ ID NO. 49 will clarify the actual sequence and position of the OB3 site 8KC (OB3)). After the pQB1064-HAL (prot) -P1-FRT-CmR-P2-8KC-HAR (pkip) plasmid was linearized, the DNA fragments were recovered by gel recovery.

[0244] The DNA fragment HAL(prot)-P1-FRT-CmR-P2-8KC-HAR(pkip) was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac, and the monoclonal bacterial solution of pKD46 / CmR-8KC(OB3)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, CmR-8KC(OB3)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.

[0245] 2 Obtain recombinant baculovirus R0335 {rBEV-8KC (OB3)}

[0246] The CmR-8KC(OB3)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0335{rBEV-8KC(OB3)}#P0 was obtained, which was transferred into suspension Sf9 cells and cultured for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells to obtain a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 minutes, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0335{rBEV-8KC(OB3)}#P1. The genome diagram of R0335{rBEV-8KC(OB3)} is shown in the figure. Figure 12 .

[0247] 3. Two baculovirus-infected host cells to package recombinant adeno-associated virus R0335-AAV8-EGFP

[0248] R0335{rBEV-8KC(OB3)}#P1 and R0004{rBEV-EGFP(Tn7)}#P1 were inoculated into suspension Sf9 cells at an MOI of 0.05 and cultured for 3 days. The viruses were then harvested and used to purify the recombinant adeno-associated virus R0335-AAV8-EGFP.

[0249] Example 10. Obtaining the recombinant baculovirus loaded with ITR-EGFP at the OB3 insertion site, R0336 {rBEV-ITR-EGFP (OB3)}, and two baculovirus-infected host cells to package the recombinant adeno-associated virus R0336-AAV8-EGFP

[0250] 1. Preparation of CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac competent cells

[0251] The ITR-EGFP packaging element expression cassette (sequence shown in SEQ ID NO. 6) obtained by enzyme digestion and gel recovery in Example 2 was used to linearize the DNA fragment. The HAL (prot) (478 bp), HAR (pkip) (428 bp), P1-FRT-CmR-P2 (1053 bp) and ITR-EGFP packaging element expression cassette (sequence shown in SEQ ID NO. 6) were linearized using the molecular cloning and recombination method of restriction enzyme cutting sites. The DNA fragments were cloned on the vector plasmid pQB1064 to obtain the pQB1064-HAL (prot) -P1-FRT-CmR-P2-ITR-EGFP-HAR (pkip) plasmid (SEQ ID NO. 50, the vector sequence of SEQ ID NO. 50 will clarify the actual sequence and position of EGFP (OB3) at the OB3 site). The pQB1064-HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) plasmid was linearized and the DNA fragment HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) was recovered by gel extraction. This DNA fragment was transformed into the L-arabinose-induced electroporation competent cell of pKD46 / ΔCC-DH10Bac. The monoclonal bacterial solution of pKD46 / CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac was screened and identified. After culturing at 42°C to eliminate the pKD46 plasmid, the competent cells of CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac were prepared by resistance plate screening.

[0252] 2 Obtain recombinant baculovirus R0336 {rBEV-ITR-EGFP (OB3)}

[0253] The CmR-ITR-EGFP(OB3)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant Bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0336{rBEV-ITR-EGFP(OB3)}#P0 was obtained, which was transferred into suspension Sf9 cells and cultured for 3 days. The recombinant baculovirus that replicated and proliferated in large quantities further infected the Sf9 cells to obtain a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 minutes, and the supernatant was aliquoted and stored, which was the harvested recombinant baculovirus R0336{rBEV-ITR-EGFP(OB3)}#P1. The genome diagram of R0336{rBEV-ITR-EGFP(OB3)} is shown in the figure. Figure 13 The fluorescence photos of cells grown from R0336{rBEV-ITR-EGFP(OB3)}#P1 to P7 at a fixed inoculation starting density and MOI are shown in the figure below. Figure 15 As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB3 site remained stable in the P7 generation.

[0254] 3. Two baculovirus-infected host cells to package recombinant adeno-associated virus R0336-AAV8-EGFP

[0255] R0335{rBEV-8KC(OB3)}#P1 and R0336{rBEV-ITR-EGFP(OB3)}#P1 were inoculated into suspension Sf9 cells at an MOI of 0.05 and cultured for 3 days. The viruses were then harvested and used to purify the recombinant adeno-associated virus R0336-AAV8-EGFP.

[0256] Example 11. Obtaining a recombinant baculovirus with 8KC loaded at the OB1 insertion site and ITR-EGFP loaded at the OB2 insertion site, R0337 {rBEV-8KC (OB1)-ITR-EGFP (OB2)}.

[0257] 1. Preparation of GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells

[0258] The synthetic sequence FRT-pCAT-GmR (SEQ ID NO. 51) was cloned with the pQB1064-HAL(prot)-P1-FRT-CmR-P2-ITR-EGFP-HAR(pkip) plasmid (SEQ ID NO. 50, the vector sequence of SEQ ID NO. 50 will clarify the actual sequence and position of EGFP (OB3) at the OB3 site) of Example 10 using molecular cloning and recombination using restriction enzyme sites to obtain the pQB1064-HAL(prot)-P1-FRT-GmR-P2-ITR-EGFP-HAR(pkip) plasmid (SEQ ID NO. 52).

[0259] The pQB1064-HAL(prot)-P1-FRT-GmR-P2-ITR-EGFP-HAR(pkip) plasmid was cloned with HAL(p15) (412 bp) and HAR(cg30) (458 bp) obtained in Example 6 by molecular cloning recombination using restriction enzyme sites to obtain the pQB1064-HAL(p15)-P1-FRT-GmR-P2-ITR-EGFP-HAR(cg30) plasmid (SEQ ID NO. 53, SEQ ID The vector sequence of NO.53 will clarify the actual sequence and position of EGFP (OB2) at the OB2 site), and after linearizing the pQB1064-HAL (p15) -P1-FRT-GmR-P2-ITR-EGFP-HAR (cg30) plasmid, the DNA fragment HAL (p15) -P1-FRT-GmR-P2-ITR-EGFP-HAR (cg30) was recovered by gel recovery, and the DNA fragment was transformed into Example 1 to obtain The CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were screened and identified to obtain the monoclonal bacterial solution of pKD46 / GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac. After culturing at 42°C to eliminate the pKD46 plasmid, the GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were prepared by resistance plate screening.

[0260] 2 Obtain recombinant baculovirus R0337 {rBEV-8KC (OB1)-ITR-EGFP (OB2)}

[0261] The GmR-ITR-EGFP(OB2)-CmR-8KC(OB1)-ΔCC-DH10Bac competent cells were shaken to extract the recombinant bacmid DNA, which was then transfected into the host cell line for culture. After 4 days of culture, the recombinant baculovirus R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P0 was obtained, which was then transferred into suspension Sf9 cells for culture for 3 days. The massively replicated and proliferated recombinant baculovirus further infected the Sf9 cells to obtain a higher titer of seed virus. The entire cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored, namely the harvested recombinant baculovirus R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P1. The genome diagram of R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)} is shown in the figure. Figure 14The fluorescence photos of cells of R0337{rBEV-8KC(OB1)-ITR-EGFP(OB2)}#P1 were expanded to P7 at a fixed inoculation starting density and MOI. Figure 15 As shown in the figure, the expression of the target gene EGFP fluorescence inserted into the OB2 site remained stable in the P7 generation.

[0262] Example 12. The infectious titer of the recombinant baculovirus was detected using the TCID50 method of indirect immunofluorescence based on the GP64 protein expressed by the recombinant virus.

[0263] The sf9 insect cells cultured in the serum-free medium Sf-900II SFM were cultured to a viable cell density of 1-6E+6 cells / mL and a cell viability of more than 95%. The cell suspension was diluted to a viable cell density of 4.5E+5 cells / mL, and 100 μL of the cell suspension was plated on a 96-well plate. The plates were incubated at 27°C for 0.5-2 hours before infection.

[0264] The test samples R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1, R0330{rBEV-8KC-EGFP(OB1)}#P1, R0331{rBEV-8KC(OB1)-EGFP(Tn7)}#P1, R0332{rBEV-8KC(OB1)}#P1, R0004{rBEV-EGFP(Tn 7)}#P1, R0333{rBEV-8KC(OB2)}#P1, R0334{rBEV-8KC(OB2)-EGFP(Tn7)}#P1, R0335{rBEV-8KC(OB3)}#P1 and R0336{rBEV-ITR-EGFP(OB3)}#P1 were seed viruses. 100 μl of seed virus stock solution was added to 900 μl of Sf-900II culture medium. In SFM, it is 10-1, and 100 μl of seed virus stock solution is taken from 1 mL of 10-1 and added to 900 μl of culture medium Sf-900II SFM, which is 10-2. Gradual dilutions are performed in sequence to 10-9. Each gradient of each virus is inoculated into 96-well plates with Sf9 cells, 100 μL per well, and 8 replicates are inoculated for each gradient. After infection, the cells are cultured at 27°C for 96 hours, the supernatant is discarded, and the cell surface is washed once with 200 μL PBS (pH 7.2). The PBS is discarded, 150 μL of anhydrous ethanol is added, and the cells are fixed at room temperature for 10-15 minutes. The anhydrous ethanol is discarded and the cells are placed at room temperature for 2-5 minutes to dry naturally. 200 μL PBS (pH 7.2) was added to each well to wash the cell surface once, the PBS was discarded, 100 μL primary antibody working solution (Baculovirus Envelop gp64 monoclonal antibody diluted 1:500 with PBS) was added, and the plate was incubated at 37°C for 1 hour. The primary antibody working solution was discarded, and the plate was washed three times with Wash Buffer (0.05% Tween-20 in PBS) with 200 μL added each time. The plate was gently shaken for 1 minute during the washing process, and washed twice with PBS. The washing solution was discarded, and 100 μL secondary antibody working solution (Goat anti-Mouse IgG (H+L) monoclonal antibody diluted 1:300 with PBS) was added to each well. The plate was incubated at 37°C for 1 hour, the secondary antibody working solution was discarded, and the plate was washed three times with Wash Buffer (0.05% Tween-20 in PBS) with 200 μL added each time. The plate was gently shaken for 1 minute during the washing process, and washed twice with PBS. The washing solution was discarded, and 100 μL PBS was added. The wells with positive red fluorescence were observed under a fluorescence microscope and marked. The recombinant baculovirus infection titer was calculated according to the Reed-Muench method. The indirect immunofluorescence TCID50 infection titer results of various viruses are shown in Table 1:

[0265] Table 1

[0266]

[0267] Example 13. New method based on recombinant virus-expressed Gluc (OB1) to detect the infectious titer of recombinant baculovirus

[0268] The sf9 insect cells cultured in the serum-free medium Sf-900II SFM were cultured to a viable cell density of 1-6E+6 cells / mL and a cell viability of more than 95%. The cell suspension was diluted to a viable cell density of 4.5E+5 cells / mL, and 100 μL of the cell suspension was plated on a 96-well plate. The plates were incubated at 27°C for 0.5-2 hours before infection.

[0269] The R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 seed virus with a known titer of 1.311E+07TCID50 / mL was inoculated into suspended Sf9 cells at an MOI of 0.05 and cultured for 3 days before harvesting the virus. The partially packaged cell suspension was centrifuged at 3000 rpm for 5 min, and the supernatant was aliquoted and stored to obtain the harvested recombinant baculovirus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2. The remaining sample was used to purify R0329-AAV8-EGFP.

[0270] R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 was diluted to recombinant baculovirus standards with titers of 1.2E+7TCID50 / mL, 6E+6TCID50 / mL, 3E+6TCID50 / mL, 1.5E+6TCID50 / mL, and 7.5E+5TCID50 / mL, and inoculated into 96-well plates containing Sf9 cells at 100 μL per well, with three replicates.

[0271] The test sample, R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2, was inoculated into three replicates of the same 96-well plate containing Sf9 cells as the standard virus. Fresh Sf-900II SFM culture medium was used as a blank control, with 100 μL per well in triplicate. After infecting the Sf9 cells with the standard virus and the test virus for 2 hours, the medium was replaced with fresh medium and incubated for another 4 hours. 50 μL of supernatant from three wells of each sample (without centrifugation) was transferred to a new 96-well black plate. 50 μL of 1:100 luciferase assay substrate was added to each well, incubated for 5 minutes, and the cells were assayed in a chemiluminescence detector. The average of the obtained values, after subtracting the background luciferase activity from the culture medium control, was used as the actual luciferase activity value.

[0272] Use the logarithm of the viral infection titer of the standard as the abscissa and the actual luciferase activity as the ordinate to create a standard curve and linear regression equation:

[0273] Y = a × log X - b;

[0274] X: virus infectious titer, TCID50 / mL;

[0275] Y: luciferase activity value, RLU;

[0276] a, b: slope and intercept of the linear regression equation respectively;

[0277] The actual luciferase activity value of the virus sample to be tested is substituted into the linear regression equation to calculate the viral infection titer of the virus sample to be tested.

[0278] Table 2. Results of the new recombinant baculovirus luciferase titration method

[0279]

[0280] The titer of the original virus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P1 was 1.311E+07TCID50 / mL, and the titer measured by the method of the present invention was 1.39E+7 / mL, which was within the expected range. In addition, the titer of the test virus R0329{rBEV-GLuc(OB1)-8KC-EGFP(Tn7)}#P2 was 8.10E+06 / mL. The R value of the standard curve of this method was 0. 2 =0.9845, the result is reliable. Figure 16 Correlation analysis of recombinant baculovirus luciferase activity and titer.

[0281] The most widely used methods for determining the infectious titer of recombinant baculovirus in recombinant baculovirus expression systems are direct fluorescence based on background viral expression, indirect fluorescence based on immunofluorescence assays using GP64 antibodies, and flow cytometry based on fluorescent antibodies against baculovirus GP64. The direct fluorescence TCID50 method based on background viral expression is not suitable for recombinant baculoviruses that do not express the same fluorescence as the recombinant viruses produced in the system. Furthermore, the cost of using fluorescent antibodies is prohibitive. The standard curve-based method of the present application, however, enables rapid, efficient, and cost-effective viral titer determination.

[0282] Example 14. Purification of AAV and Silver Staining of Electrophoretic Gels

[0283] 10 mL of the initial mixed solution of the recombinant adeno-associated virus R0329-AAV8-EGFP collected in Example 1, the initial mixed solution of the recombinant adeno-associated virus R0330-AAV8-EGFP collected in Example 2, the initial mixed solution of the recombinant adeno-associated virus R0331-AAV8-EGFP collected in Example 4, the initial mixed solution of the recombinant adeno-associated virus R0334-AAV8-EGFP collected in Example 8, the initial mixed solution of the recombinant adeno-associated virus R0335-AAV8-EGFP collected in Example 9, and the initial mixed solution of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 were taken out and centrifuged respectively. The cell pellet and supernatant were harvested and purified separately. The cells were lysed by repeated freeze-thaw cycles three times, and the supernatant was collected by centrifugation at 5000 rpm for 10 min. The supernatant was added to the original supernatant, 10% PEG was added, and the mixture was incubated on ice at 4°C for 2 hours. The harvested pellet was resuspended in PBS, treated with nuclease (Benzonase) in a 37°C water bath for 60 minutes, and the supernatant was collected by centrifugation at 5000 rpm for 10 minutes. The supernatant was then separated and purified by iodixanol density gradient centrifugation (see Aslanidi et al., 2009, Proc. Natl Acad. Sci. USA, 206:5059-5064). The purified virus was resuspended in 80 μL PBS, and 10 μL of the purified virus was run on an SDS-PAGE gel and stained.

[0284] The results of the purified virus infection of each recombinant baculovirus system model are as follows Figure 17 . Lanes 1, 2, 3, 4, 5, and 6 are, respectively, the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0329-AAV8-EGFP collected in Example 1, the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0330-AAV8-EGFP collected in Example 2, the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0331-AAV8-EGFP collected in Example 4, the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0334-AAV8-EGFP collected in Example 8, the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0335-AAV8-EGFP collected in Example 9, and the finished viruses purified from the initial mixture of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10. The sample volume is 20 μL for each. The titer of the finished virus purified from the initial mixture of the recombinant adeno-associated virus R0336-AAV8-EGFP collected in Example 10 is low, and only faint shadows can be seen for VP1 and VP2.

[0285] Based on the above examples of the present application, it can be seen that the present application screened out new insertion sites OB1, OB2 and OB3 in the recombinant baculovirus (BEV) genome that can allow stable expression of exogenous genes, and loaded luciferase (Luciferase) reporter gene expression cassettes and necessary functional elements of recombinant adeno-associated virus at the new sites, so that the recombinant baculovirus genome BEV can be packaged at three sites based on one, two or more component versions of the baculovirus system for recombinant adeno-associated virus; and invented a new method for measuring the infection titer of recombinant baculovirus based on the Luciferase reporter gene expressed by the very early promoter. When measuring the titer of the recombinant baculovirus constructed according to the method of the present invention, the virus sample does not need to be diluted, and the virus titer is measured within 4 hours after the medium is replaced 2 hours after the cells are infected. There is no need to observe cell pathology, fluorescence or staining, and the operation is simple, time-saving and cost-effective.

[0286] In summary, the present application is based on the concept of recombinant baculovirus conserved loci, and uses the termination codons of the conserved loci to insert exogenous genes at sites that are reversely overlapped, directly connected, or connected to a connecting sequence, thereby minimizing disruption to the expression of existing known and unknown functional elements. New insertion sites of the recombinant baculovirus genome that can stably carry exogenous genes are explored and screened. The use of new insertion sites has resulted in a recombinant baculovirus system with greater flexibility and compatibility. The infectious titer determination method of the present application is more convenient, more accurate, and less costly.

[0287]

[0288] SEQ ID NO.2:

[0289] GCCGCCctgGCTGCCGACGGTTATCTACCCGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAG

[0290] TGGTGGGCCCTCAAACCCGGCGCTCCTAAGCCAAAGGCTAACCAACAGAAACAAGACGACGGACGC

[0291] GGCCTGGTTCTCCCCGGTTACAAATACCTAGGACCCTTCAACGGGCTGGACAAGGGCGAACCCGTGA

[0292] ACGCTGCGGACGCCGCTGCCCTTGAGCACGATAAGGCTTACGACCAGCAACTGCAGGCCGGCGACA

[0293] ACCCTTACCTTCGTTATAACCACGCCGACGCTGAATTCCAGGAGCGTCTGCAAGAAGATACGTCTTTT

[0294] GGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTG

[0295] AGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGAGACCGGTAGAGCCATCACCCCAGCGTTCTCCAG

[0296] ACTCCTCTACGGGCATCGGCAAGAAAGGCCAACAGCCCGCCAGAAAAAGACTCAATTTTGGTCAGAC

[0297] TGGCGACTCAGAGTCAGTTCCAGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTG

[0298] GGACCTAATACAATGGCTGCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGCGCCGACGGA

[0299] GTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAG

[0300] CACCCGAACCTGGGCCCTGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACATCG

[0301] GGAGGAGCCACCAACGACAACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACA

[0302] GATTCCACTGCCACTTTTCACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCC

[0303] AAGAGACTCAGCTTCAAGCTCTTCAACATCCAGGTCAAGGAGGTCACGCAGAATGAAGGCACCAAG

[0304] ACCATCGCCAATAACCTCACCAGCACCATCCAGGTGTTTACGGACTCGGAGTACCAGCTGCCGTACGT

[0305] TCTCGGCTCTGCCCACCAGGGCTGCCTGCCTCCGTTCCCGGCGGACGTGTTCATGATTCCCCAGTACG

[0306] GCTACCTAACACTCAACAACGGTAGTCAGGCCGTGGGACGCTCCTCCTTCTACTGCCTGGAATACTTT

[0307] CCTTCGCAGATGCTGAGAACCGGCAACAACTTCCAGTTTACTTACACCTTCGAGGACGTGCCTTTCCA

[0308] CAGCAGCTACGCCCACAGCCAGAGCTTGGACCGGCTGATGAATCCTCTGATTGACCAGTACCTGTACT

[0309] ACTTGTCTCGGACTCAAACAACAGGAGGCACGGCAAATACGCAGACTCTGGGCTTCAGCCAAGGTG

[0310] GGCCTAATACAATGGCCAATCAGGCAAAGAACTGGCTGCCAGGACCCTGTTACCGCCAACAACGCGT

[0311] CTCAACGACAACCGGGCAAAACAACAATAGCAACTTTGCCTGGACTGCTGGGACCAAATACCATCTG

[0312] AATGGAAGAAATTCATTGGCTAATCCTGGCATCGCTATGGCAACACACAAAGACGACGAGGAGCGTT

[0313] TTTTTCCCAGTAACGGGATCCTGATTTTTGGCAAACAAAATGCTGCCAGAGACAATGCGGATTACAGC

[0314] GATGTCATGCTCACCAGCGAGGAAGAAATCAAAACCACTAACCCTGTGGCTACAGAGGAATACGGTA

[0315] TCGTGGCAGATAACTTGCAGCAGCAAAACACGGCTCCTCAAATTGGAACTGTCAACAGCCAGGGGGC

[0316] CTTACCCGGTATGGTCTGGCAGAACCGGGACGTGTACCTGCAGGGTCCCATCTGGGCCAAGATTCCTC

[0317] ACACGGACGGCAACTTCCACCCGTCTCCGCTGATGGGCGGCTTTGGCCTGAAACATCCTCCGCCTCA

[0318] GATCCTGATCAAGAACACGCCTGTACCTGCGGATCCTCCGACCACCTTCAACCAGTCAAAGCTGAAC

[0319] TCTTTCATCACGCAATACAGCACCGGACAGGTCAGCGTGGAAATTGAATGGGAGCTGCAGAAGGAAA

[0320] ACAGCAAGCGCTGGAACCCCGAGATCCAGTACACCTCCAACTACTACAAATCTACAAGTGTGGACTT

[0321] TGCTGTTAATACAGAAGGCGTGTACTCTGAACCCCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAA。

[0322] SEQ ID NO.3:

[0323] gccgccCtgGcggggttttacgagattgtgattaaggtccccagcgaccttgacgagcatctgcccggcatttctgacagctttgtgaactgggtggccgagaagga

[0324] GtgggagttgccgccagattctgacTtggatctgaatctgattgagcaggcacccctgaccgtggccgagaagctgcagcgcgactttctgacggaGtggcgccg

[0325] tgtgagtaaggccccggaggctcttttctttgtgcaatttgagaagggagagagctacttccacTtgcacgtgctcgtggaaaccaccggggtgaaatccTtggttttg

[0326] ggacgtttcctgagtcagattcgcgaaaaactgattcagagaatttaccgcgggatcgagccgactttgccaaactggttcgcggtcacaaagaccagaaaCggcgc

[0327] cggaggcgggaacaaggtggtggaCgagtgctacatccccaattacttgctccccaaaacccagcctgagctccagtgggcgtggactaatTtggaacagtattta

[0328] agcgcctgtttgaatctcacggagcgtaaacggttggtggcgcagcatctgacgcacgtgtcgcagacgcaggagcagaacaaagagaatcagaatcccaattctg

[0329] aCgcgccggtgatcagatcaaaaacttcagccaggtacatggagctggtcgggtggctcgtggacaaggggattacctcggagaagcagtggatTcaggaggac

[0330] caggcctcatacatctccttcaatgcggcctccaactcgcggtcccaaatcaaggctgccttggacaatgcgggaaagattatgagcctgactaaaaccgcccccga

[0331] ctacctggtgggccagcagcccgtggaggacatttccagcaatcggatttataaaattttggaactaaacgggtacgatccccaatatgcggcttccgtctttctgggat

[0332] gggccacgaaaaagttcggcaagaggaacaccatctggctgtttgggcctgcaactaccgggaagaccaacatcgcggaggccatagcccacactgtgcccttcta

[0333] cgggtgcgtaaactggaccaatgagaactttcccttcaacgactgtgtcgacaagatggtgatctggtgggaggaggggaagatgaccgccaaggtcgtggagtcg

[0334] gccaaagccattctcggaggaagcaaggtgcgcgtggaccagaaatgcaagtcctcggcccagatagacccgactcccgtgatcgtcacctccaacaccaacatgt

[0335] gcgccgtgattgacgggaactcaacgaccttcgaacaccagcagccgttgcaagaccggatgttcaaatttgaactcacccgccgtctggatcatgactttgggaag

[0336] gtcaccaagcaggaagtcaaagactttttccggtgggcaaaggatcacgtggttgaggtggagcatgaattctacgtcaaaaagggtggagccaagaaaagacccg

[0337] cccccagtgacgcagatataagtgagcccaaacgggtgcgcgagtcagttgcgcagccatcgacgtcagacgcggaGgcttcgatcaactacgcagacaggtac

[0338] caaaacaaatgttctcgtcacgtgggcatgaatctgatgctgtttccctgcagacaatgcgagagaatgaatcagaattcaaatatctgcttcactcacggacagaaaga

[0339] ctgtttagagtgctttcccgtgtcagaatctcaacccgtttctgtcgtcaaaaaggcgtatcagaaactgtgctacattcatcatatcatgggaaaggtgccagacgcttgcactgcctgcgatctggtcaatgtggatttggatgactgcatctttgaacaataa。

[0340] SEQ ID No.4:

[0341] Cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcaaagcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcct。

[0342] SEQ ID No.5:

[0343] Aggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg。

[0344] SEQ ID NO.6:

[0345] cctgcaggcagctgcgcgctcgctcgctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggag

[0346] tggccaactccatcactaggggttcctgcggccgcacgcgtgtgtctagaacgcgtggagctagttattaatagtaatcaattacggggtcattagttcatagcccatata

[0347] tggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaat

[0348] agggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacg

[0349] gtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcag

[0350] tacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaa

[0351] atgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagac

[0352] gccatccacgctgttttgacctccatagaagacaccgggaccgatccagcctccggtaccgaaaaccccggtccggctagcgccaccggatccggcggatctggc

[0353] atggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcga

[0354] gggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgca

[0355] gtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggc

[0356] aactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggc

[0357] acaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacg

[0358] gcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagc

[0359] aaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagggctccggagactac

[0360] aaggatgacgatgacaaggattacaaagacgacgatgataaggactataaggatgatgacgacaaataaaagctttaaaccggttatcgataatcaacctctggatta

[0361] caaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttct

[0362] cctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg

[0363] cattgccaccacctgtcagctcctttccggaactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcgg

[0364] ctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcc

[0365] cttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggcc

[0366] gcctccccgcatcgataccgagcgctgctcgagagatctacgggtggcatccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgccc

[0367] accagccttgtcctaataaaattaagttgcatcattttgtctgactaggtgtccttctataatattatggggtggaggggggtggtatggagcaaggggcaagttgggaag

[0368] acaacctgtagggcctgcggggtctattgggaaccaagctggagtgcagtggcacaatcttggctcactgcaatctccgcctcctgggttcaagcgattctcctgcctc

[0369] agcctcccgagttgttgggattccaggcatgcatgaccaggctcagctaatttttgtttttttggtagagacggggtttcaccatattggccaggctggtctccaactccta

[0370] atctcaggtgatctacccaccttggcctcccaaattgctgggattacaggcgtgaaccactgctcccttccctgtccttctgattttgtaggtaaccacgtgcggaccgag

[0371] cggccgcaggaacccctagtgatggagttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcagg。

[0372] SEQ ID NO.7:

[0373] Gggtgtacaggtaacggccaattcaacgtgacgatgcgcacgtcctcgggtatgcatttgttaaaaaacacacagctcgctttaccaaacgaaagcaaaggtactaa

[0374] atatggcgccattggctgatttgttattccaagataattacaaataaactgatccgtcgtggggtgataactggcaggtgtcagctttaaataatcttcaacgttgttgtcgc

[0375] gcaaaagtctgcattttacacgcgttgttaatcccacgacttttgcatgtaaaatcggatccaaatactgcagaatcgtgtctataatttctaatggtaaacgtatgcgttttgctcgtgggcgctttgtaacgctcgacatcctaataacaactaacacaaaactaaaatgatactcaatatattgcttCCCGGGGGGA。

[0376] SEQ ID NO.8:

[0377] ACATGcatgctctcaacacactcgctatttggaacataatcatatcgtctcagtagctcaaggtagagcgtagcgctctggatcgtatagatcttgctaaggttgtgag

[0378] ttcaagtctcgcctgagatattaaaaaactttgtaattttaaaaattttattttataatatacaattaaaaactatacaattttttattattacattaataatgatacaatttttattattac

[0379] atttaatattgtctattacggtttctaatcatacagtacaaaaataaaatcacaattaatataattacaaagttaactacatgaccaaacatgaacgaagtcaatttagcggccaattcgccttcagccatggaagtgatgtcgctcagactggtgccgacgccgccaaacttggtgttctccagtttaaacaaagct。

[0380] SEQ ID NO. 9:

[0381] ctaGCTAGCgtgtaggctggagctgcttcgaagttcctatactttctagagaataggaacttcggaataggaacttcatttaaatggcgcgccttacgccccgccct

[0382] gccactcatcgcagtactgttgtaattcattaagcattctgccgacatggaagccatcacaaacggcatgatgaacctgaatcgccagcggcatcagcaccttgtcgcc

[0383] ttgcgtataatatttgcccatggtgaaaacgggggcgaagaagttgtccatattggccacgtttaaatcaaaactggtgaaactcacccagggattggctgagacgaaa

[0384] aacatattctcaataaaccctttagggaaataggccaggttttcaccgtaacacgccacatcttgcgaatatatgtgtagaaactgccggaaatcgtcgtggtattcactc

[0385] cagagcgatgaaaacgtttcagtttgctcatggaaaacggtgtaacaagggtgaacactatcccatatcaccagctcaccgtctttcattgccatacgtaattccggatg

[0386] agcattcatcaggcgggcaagaatgtgaataaaggccggataaaacttgtgcttatttttctttacggtctttaaaaaggccgtaatatccagctgaacggtctggttatag

[0387] gtacattgagcaactgactgaaatgcctcaaaatgttctttacgatgccattgggatatatcaacggtggtatatccagtgatttttttctccattttagcttccttagctcctga

[0388] aaatctcgacaactcaaaaaatacgcccggtagtgatcttatttcattatggtgaaagttggaacctcttacgtgccgatcaacgtctcattttcgccaaaagttggcccag

[0389] ggcttcccggtatcaacagggacaccaggatttatttattctgcgaagtgatcttccgtcacaggtaggcgcgccgaagttcctatactttctagagaataggaacttcggaataggaactaaggaggatattcatatggaccatggctaattcccatAAGCTTggg。

[0390] SEQ ID NO.10:

[0391] ccaAtgcattcatacgctatagatccggtgacggccatcgaatgtataaactacatgaacaacaacgtgcaaagcgtcacgttgaccgacacttgccccgcaattgaa

[0392] ttgcggtttcagcaattttttgatccaccgctacagcagagcaattacatgaccgtgtccgtggacgggtatgtcgtgctcgacaccgagttgagatacgtcaaatataaa

[0393] tggatgccaacaaccgagttagagtatgacgccgtgaataagtcgtttaacacactcaatgggccattgaacggtctcatgattttaaccgacttgccggagttactgcacgaaaacatttacgaatgtgtaatcacggacacgacaataaacgtgttgaaacatcgtcgcgaccgaatcgtgccaaattaacccgggggt。

[0394] SEQ ID NO.11:

[0395] acatGcatgcttaaagcacgttaagcggatacaacgggcagtccgagctgttaaagtcaatacaaccatcgttaacaaacgaatacgcattgttgtgacagctgagga

[0396] tataaaaaggaatagagaagtaattgcaatgaaatatcccgttacaattccacggcacagcgtatgttgctcgagttctatcagttgcacacaacggcctaagaaaattta

[0397] ttaatgcttcatttgtatctatattagaaggataatacataggttcgcccaaaggactgggagaaggcggcggcgaaggtgtaggtgtaggaggaataggagaaggtggag gtttaaacaaagct。

[0398] SEQ ID NO.12:

[0399] CCTCGAGGcgccggcggtcgaaggcactcgcttcgatcaatggacaaagaatcaatcgttcgtaggcaacagaatgtcggaaagtttgcattggatgcgcgg

[0400] cgggtccaacttgccgcaaaactgcggcgagttcaacgtggtgtccagcctgttgatgtgcaacaatacgataatgaaaaattgataacgcttgcacgattgcaaacat

[0401] gcacgctcggttgaataaaagctcgcatcgtcgtcgtaaaattagttgtatcaaagagcagctgcaattagaatcactgctaaaaAGATCTGCCGCCATG

[0402] GGAGTCAAAGTTCTGTTTGCCCTGATCTGCATCGCTGTGGCCGAGGCCAAGCCCACCGAGAACAACG

[0403] AAGACTTCAACATCGTGGCCGTGGCCAGCAACTTCGCGACCACGGATCTCGATGCTGACCGCGGGAA

[0404] GTTGCCCGGCAAGAAGCTGCCGCTGGAGGTGCTCAAAGAGTTGGAAGCCAATGCCCGGAAAGCTGG

[0405] CTGCACCAGGGGCTGTCTGATCTGCCTGTCCCACATCAAGTGCACGCCCAAGATGAAGAAGTTCATCC

[0406] CAGGACGCTGCCACACCTACGAAGGCGACAAAGAGTCCGCACAGGGCGGCATAGGCGAGGCGATCG

[0407] TCGACATTCCTGAGATTCCTGGGTTCAAGGACTTGGAGCCCTTGGAGCAGTTCATCGCACAGGTCGAT

[0408] CTGTGTGTGGACTGCACAACTGGCTGCCTCAAAGGGCTTGCCAACGTGCAGTGTTCTGACCTGCTCA

[0409] AGAAGTGGCTGCCGCAACGCTGTGCGACCTTTGCCAGCAAGATCCAGGGCCAGGTGGACAAGATCA

[0410] AGGGGGCCGGTGGTGACTAATCTAGAGTCGGGGCGGCCGGCCGCTTCGAGCAGACATGATAAGATAC

[0411] ATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGA

[0412] TGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTGATATCGCGGCCGCGCTAGCGcatgc。

[0413] SEQ ID NO.13:

[0414] cctaggctcgaggcatgcAGATCTGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAG

[0415] AATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC

[0416] TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA

[0417] GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCCTCTAGTACTTCTCGA

[0418] Cacctgatttaaatcatttattgttcaaagatgcagtcatccaaatccacattgaccagatcgcaggcagtgcaagcgtctggcacctttcccatgatatgatgaatgtag

[0419] cacagtttctgatacgcctttttgacgacagaaacgggttgagattctgacacgggaaagcactctaaacagtctttctgtccgtgagtgaagcagatatttgaattctgat

[0420] tcattctctcgcattgtctgcagggaaacagcatcagattcatgcccacgtgacgagaacatttgttttggtacctgtctgcgtagttgatcgaagcCtccgcgtctgacg

[0421] tcgatggctgcgcaactgactcgcgcacccgtttgggctcacttatatctgcgtcactgggggcgggtcttttcttggctccaccctttttgacgtagaattcatgctccac

[0422] ctcaaccacgtgatcctttgcccaccggaaaaagtctttgacttcctgcttggtgaccttcccaaagtcatgatccagacggcgggtgagttcaaatttgaacatccggtc

[0423] ttgcaacggctgctggtgttcgaaggtcgttgagttcccgtcaatcacggcgcacatgttggtgttggaggtgacgatcacgggagtcgggtctatctgggccgagga

[0424] cttgcatttctggtccacgcgcaccttgcttcctccgagaatggctttggccgactccacgaccttggcggtcatcttcccctcctcccaccagatcaccatcttgtcgac

[0425] acagtcgttgaagggaaagttctcattggtccagtttacgcacccgtagaagggcacagtgtgggctatggcctccgcgatgttggtcttcccggtagttgcaggccca

[0426] aacagccagatggtgttcctcttgccgaactttttcgtggcccatcccagaaagacggaagccgcatattggggatcgtacccgtttagttccaaaattttataaatccga

[0427] ttgctggaaatgtcctccacgggctgctggcccaccaggtagtcgggggcggttttagtcaggctcataatctttcccgcattgtccaaggcagccttgatttgggaccg

[0428] cgagttggaggccgcattgaaggagatgtatgaggcctggtcctcctgAatccactgcttctccgaggtaatccccttgtccacgagccacccgaccagctccatgta

[0429] cctggctgaagtttttgatctgatcaccggcgcGtcagaattgggattctgattctctttgttctgctcctgcgtctgcgacacgtgcgtcagatgctgcgccaccaaccg

[0430] tttacgctccgtgagattcaaacaggcgcttaaatactgttccaAattagtccacgcccactggagctcaggctgggttttggggagcaagtaattggggatgtagcac

[0431] tcGtccaccaccttgttcccgcctccggcgccGtttctggtctttgtgaccgcgaaccagtttggcaaagtcggctcgatcccgcggtaaattctctgaatcagtttttcg

[0432] cgaatctgactcaggaaacgtcccaaaaccaAggatttcaccccggtggtttccacgagcacgtgcaAgtggaagtagctctctcccttctcaaattgcacaaagaa

[0433] aagagcctccggggccttactcacacggcgccaCtccgtcagaaagtcgcgctgcagcttctcggccacggtcaggggtgcctgctcaatcagattcagatccaA

[0434] gtcagaatctggcggcaactcccaCtccttctcggccacccagttcacaaagctgtcagaaatgccgggcagatgctcgtcaaggtcgctggggaccttaatcacaa

[0435] tctcgtaaaaccccgCcaGggcggcGACCGCGCCCGATGGTGGGACGGTATGAATAATCCGTATTTATAGGTTTTTT

[0436] TATTACAAAACTGTTACGAAAACAGTAAAATACTTATTTATTTGCGAGATGGTTATCATTTTAATTATCTC

[0437] CATGATCTATTAATATTCCTGCAGGCCGGAGTATACGGACCTTTAATTCAACCCAACACAATATATTATA

[0438] GTTAAATAAGAATTATTATCAAATCATTTGTATATTAATTAAAATACTATACTGTAAATTACATTTTATTTA

[0439] CAATCACTCGACcAAGACTTACACCCGGGggTtccgttaagGCCGCCACGGCTGCCGACGGTTATCTACCCG

[0440] ATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGCtCTCAAACCCGGCGCTCCTAAG

[0441] CCAAAGGCTAACCAACAGAAACAAGACGACGGcCGCGGCCTtGTTCTCCCCGGTTACAAATACCTcGG

[0442] ACCCTTCAACGGGCTcGACAAGGGCGAACCCGTGAACGCgGCGGACGCCGCgGCCCTTGAGCACGAT

[0443] AAGGCTTACGACCAaCAACTcCAGGCCGGCGACAACCCTTACCTTCGTTATAACCACGCCGACGCcGA

[0444] ATTCCAGGAGCGTCTcCAAGAAGATACcTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCA

[0445] AGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGA

[0446] GACCGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAACA

[0447] GCCCGCCAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTCAGTTCCAGACCCTCAACCT

[0448] CTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGACCTAATACAATGGCTGCAGGCGGTGGCGCAC

[0449] CAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTC

[0450] CACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAAC

[0451] CACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAACGACAACACCTACTTCGGCT

[0452] ACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAG

[0453] CGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAGCTTCAAGCTCTTCAACATCCAGG

[0454] TCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCACCAGCACCATCCAGGT

[0455] GTTTACGGACTCGGAGTACCAGCTGCCGTACGTTCTCGGCTCTGCCCACCAGGGCTGCCTGCCTCCGT

[0456] TCCCGGCGGACGTGTTCATGATTCCCCAGTACGGCTACCTAACACTCAACAACGGTAGTCAGGCCGTG

[0457] GGACGCTCCTCCTTCTACTGCCTGGAATACTTTCCTTCGCAGATGCTGAGAACCGGCAACAACTTCCA

[0458] GTTTACTTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCCCACAGCCAGAGCTTGGACCGG

[0459] CTGATGAATCCTCTGATTGACCAGTACCTGTACTACTTGTCTCGGACTCAAACAACAGGAGGCACGGC

[0460] AAATACGCAGACTCTGGGCTTCAGCCAAGGTGGGCCTAATACAATGGCCAATCAGGCAAAGAACTGG

[0461] CTGCCAGGACCCTGTTACCGCCAACAACGCGTCTCAACGACAACCGGGCAAAACAACAATAGCAAC

[0462] TTTGCCTGGACTGCTGGGACCAAATACCATCTGAATGGAAGAAATTCATTGGCTAATCCTGGCATCGCT

[0463] ATGGCAACACACAAAGACGACGAGGAGCGTTTTTTTCCCAGTAACGGGATCCTGATTTTTGGCAAAC

[0464] AAAATGCTGCCAGAGACAATGCGGATTACAGCGATGTCATGCTCACCAGCGAGGAAGAAATCAAAAC

[0465] CACTAACCCTGTGGCTACAGAGGAATACGGTATCGTGGCAGATAACTTGCAGCAGCAAAACACGGCT

[0466] CCTCAAATTGGAACTGTCAACAGCCAGGGGGCCTTACCCGGTATGGTCTGGCAGAACCGGGACGTGT

[0467] ACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCACCCGTCTCCGCTGATG

[0468] GGCGGCTTTGGCCTGAAACATCCTCCGCCTCAGATCCTGATCAAGAACACGCCTGTACCTGCGGATCC

[0469] TCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTTCATCACGCAATACAGCACCGGACAGGTCAGC

[0470] GTGGAAATTGAATGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCCGAGATCCAGTACACC

[0471] TCCAACTACTACAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCGTGTACTCTGAACCCCG

[0472] CCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAAAGCTGGGGAGATGGGGGAGGCTAACTGAAA

[0473] CACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGC

[0474] ACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcgacatgtcctgcaggcagctgcgcgctcgctcgctcactgaggccgcccggg

[0475] cgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtgtgtct

[0476] agaacgcgtggagctagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctga

[0477] ccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgc

[0478] ccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggact

[0479] ttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttccaagt

[0480] ctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtg

[0481] tacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgatcca

[0482] gcctccggtaccgaaaaccccggtccggctagcgccaccggatccggcggatctggcatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcct

[0483] ggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcacca

[0484] ccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaa

[0485] gtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggt

[0486] gaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccga

[0487] caagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggc

[0488] gacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtg

[0489] accgccgccgggatcactctcggcatggacgagctgtacaagggctccggagactacaaggatgacgatgacaaggattacaaagacgacgatgataaggactat

[0490] aaggatgatgacgacaaataaaagctttaaaccggttatcgataatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgct

[0491] atgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgtt

[0492] gtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccggaactttcgctttccccctccct

[0493] attgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttc

[0494] cttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggct

[0495] ctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcgataccgagcgctgctcgagagatctacgggtggc

[0496] atccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcctaataaaattaagttgcatcattttgtctgactaggtgtc

[0497] cttctataatattatggggtggaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggcctgcggggtctattgggaaccaagctggagtgca

[0498] gtggcacaatcttggctcactgcaatctccgcctcctgggttcaagcgattctcctgcctcagcctcccgagttgttgggattccaggcatgcatgaccaggctcagcta

[0499] atttttgtttttttggtagagacggggtttcaccatattggccaggctggtctccaactcctaatctcaggtgatctacccaccttggcctcccaaattgctgggattacagg

[0500] cgtgaaccactgctcccttccctgtccttctgattttgtaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctgcgc

[0501] gctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcaggggcgcccctcgagg。

[0502] SEQ ID NO.14:

[0503] cctaggctcgaggcatgcAGATCTGATCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAG

[0504] AATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGC

[0505] TGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGA

[0506] GGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATCCTCTAGTACTTCTCGA

[0507] Cacctgatttaaatcatttattgttcaaagatgcagtcatccaaatccacattgaccagatcgcaggcagtgcaagcgtctggcacctttcccatgatatgatgaatgtag

[0508] cacagtttctgatacgcctttttgacgacagaaacgggttgagattctgacacgggaaagcactctaaacagtctttctgtccgtgagtgaagcagatatttgaattctgat

[0509] tcattctctcgcattgtctgcagggaaacagcatcagattcatgcccacgtgacgagaacatttgttttggtacctgtctgcgtagttgatcgaagcCtccgcgtctgacg

[0510] tcgatggctgcgcaactgactcgcgcacccgtttgggctcacttatatctgcgtcactgggggcgggtcttttcttggctccaccctttttgacgtagaattcatgctccac

[0511] ctcaaccacgtgatcctttgcccaccggaaaaagtctttgacttcctgcttggtgaccttcccaaagtcatgatccagacggcgggtgagttcaaatttgaacatccggtc

[0512] ttgcaacggctgctggtgttcgaaggtcgttgagttcccgtcaatcacggcgcacatgttggtgttggaggtgacgatcacgggagtcgggtctatctgggccgagga

[0513] cttgcatttctggtccacgcgcaccttgcttcctccgagaatggctttggccgactccacgaccttggcggtcatcttcccctcctcccaccagatcaccatcttgtcgac

[0514] acagtcgttgaagggaaagttctcattggtccagtttacgcacccgtagaagggcacagtgtgggctatggcctccgcgatgttggtcttcccggtagttgcaggccca

[0515] aacagccagatggtgttcctcttgccgaactttttcgtggcccatcccagaaagacggaagccgcatattggggatcgtacccgtttagttccaaaattttataaatccga

[0516] ttgctggaaatgtcctccacgggctgctggcccaccaggtagtcgggggcggttttagtcaggctcataatctttcccgcattgtccaaggcagccttgatttgggaccg

[0517] cgagttggaggccgcattgaaggagatgtatgaggcctggtcctcctgAatccactgcttctccgaggtaatccccttgtccacgagccacccgaccagctccatgta

[0518] cctggctgaagtttttgatctgatcaccggcgcGtcagaattgggattctgattctctttgttctgctcctgcgtctgcgacacgtgcgtcagatgctgcgccaccaaccg

[0519] tttacgctccgtgagattcaaacaggcgcttaaatactgttccaAattagtccacgcccactggagctcaggctgggttttggggagcaagtaattggggatgtagcac

[0520] tcGtccaccaccttgttcccgcctccggcgccGtttctggtctttgtgaccgcgaaccagtttggcaaagtcggctcgatcccgcggtaaattctctgaatcagtttttcg

[0521] cgaatctgactcaggaaacgtcccaaaaccaAggatttcaccccggtggtttccacgagcacgtgcaAgtggaagtagctctctcccttctcaaattgcacaaagaa

[0522] aagagcctccggggccttactcacacggcgccaCtccgtcagaaagtcgcgctgcagcttctcggccacggtcaggggtgcctgctcaatcagattcagatccaA

[0523] gtcagaatctggcggcaactcccaCtccttctcggccacccagttcacaaagctgtcagaaatgccgggcagatgctcgtcaaggtcgctggggaccttaatcacaa

[0524] tctcgtaaaaccccgCcaGggcggcGACCGCGCCCGATGGTGGGACGGTATGAATAATCCGTATTTATAGGTTTTTT

[0525] TATTACAAAACTGTTACGAAAACAGTAAAATACTTATTTATTTGCGAGATGGTTATCATTTTAATTATCTC

[0526] CATGATCTATTAATATTCCTGCAGGCCGGAGTATACGGACCTTTAATTCAACCCAACACAATATATTATA

[0527] GTTAAATAAGAATTATTATCAAATCATTTGTATATTAATTAAAATACTATACTGTAAATTACATTTTATTTA

[0528] CAATCACTCGACcAAGACTTACACCCGGGggTtccgttaagGCCGCCACGGCTGCCGACGGTTATCTACCCG

[0529] ATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGCtCTCAAACCCGGCGCTCCTAAG

[0530] CCAAAGGCTAACCAACAGAAACAAGACGACGGcCGCGGCCTtGTTCTCCCCGGTTACAAATACCTcGG

[0531] ACCCTTCAACGGGCTcGACAAGGGCGAACCCGTGAACGCgGCGGACGCCGCgGCCCTTGAGCACGAT

[0532] AAGGCTTACGACCAaCAACTcCAGGCCGGCGACAACCCTTACCTTCGTTATAACCACGCCGACGCcGA

[0533] ATTCCAGGAGCGTCTcCAAGAAGATACcTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCA

[0534] AGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACGGCTCCTGGAAAGAAGA

[0535] GACCGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCGGCAAGAAAGGCCAACA

[0536] GCCCGCCAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTCAGTTCCAGACCCTCAACCT

[0537] CTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGACCTAATACAATGGCTGCAGGCGGTGGCGCAC

[0538] CAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTC

[0539] CACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAAC

[0540] CACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAACGACAACACCTACTTCGGCT

[0541] ACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTTTCACCACGTGACTGGCAG

[0542] CGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAGCTTCAAGCTCTTCAACATCCAGG

[0543] TCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCACCAGCACCATCCAGGT

[0544] GTTTACGGACTCGGAGTACCAGCTGCCGTACGTTCTCGGCTCTGCCCACCAGGGCTGCCTGCCTCCGT

[0545] TCCCGGCGGACGTGTTCATGATTCCCCAGTACGGCTACCTAACACTCAACAACGGTAGTCAGGCCGTG

[0546] GGACGCTCCTCCTTCTACTGCCTGGAATACTTTCCTTCGCAGATGCTGAGAACCGGCAACAACTTCCA

[0547] GTTTACTTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCCCACAGCCAGAGCTTGGACCGG

[0548] CTGATGAATCCTCTGATTGACCAGTACCTGTACTACTTGTCTCGGACTCAAACAACAGGAGGCACGGC

[0549] AAATACGCAGACTCTGGGCTTCAGCCAAGGTGGGCCTAATACAATGGCCAATCAGGCAAAGAACTGG

[0550] CTGCCAGGACCCTGTTACCGCCAACAACGCGTCTCAACGACAACCGGGCAAAACAACAATAGCAAC

[0551] TTTGCCTGGACTGCTGGGACCAAATACCATCTGAATGGAAGAAATTCATTGGCTAATCCTGGCATCGCT

[0552] ATGGCAACACACAAAGACGACGAGGAGCGTTTTTTTCCCAGTAACGGGATCCTGATTTTTGGCAAAC

[0553] AAAATGCTGCCAGAGACAATGCGGATTACAGCGATGTCATGCTCACCAGCGAGGAAGAAATCAAAAC

[0554] CACTAACCCTGTGGCTACAGAGGAATACGGTATCGTGGCAGATAACTTGCAGCAGCAAAACACGGCT

[0555] CCTCAAATTGGAACTGTCAACAGCCAGGGGGCCTTACCCGGTATGGTCTGGCAGAACCGGGACGTGT

[0556] ACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCACCCGTCTCCGCTGATG

[0557] GGCGGCTTTGGCCTGAAACATCCTCCGCCTCAGATCCTGATCAAGAACACGCCTGTACCTGCGGATCC

[0558] TCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTTCATCACGCAATACAGCACCGGACAGGTCAGC

[0559] GTGGAAATTGAATGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCCGAGATCCAGTACACC

[0560] TCCAACTACTACAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCGTGTACTCTGAACCCCG

[0561] CCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAAAGCTGGGGAGATGGGGGAGGCTAACTGAAA

[0562] CACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcg。

[0563] SEQ ID NO.15:

[0564] ccattcgccattcaggctgcaaataagcgttgatattcagtcaattacaaacattaataacgaagagatgacagaaaaattttcattctgtgacagagaaaaagtagccg

[0565] aagatgacggtttgtcacatggagttggcaggatgtttgattaaaaacataacaggaagaaaaatgccccgctgtgggcggacaaaatagttgggaactgggagggg

[0566] tggaaatggagtttttaaggattatttagggaagagtgacaaaatagatgggaactgggtgtagcgtcgtaagctaatacgaaaattaaaaatgacaaaatagtttggaa

[0567] ctagatttcacttatctggttcggatctcctaggggcgcgcccgtcgacgcgccggcgacatgtcctgcaggcagctgcgcgctcgctcgctcactgaggccgcccg

[0568] ggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcctgcggccgcacgcgtgtg

[0569] tctagaacgcgtggagctagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggct

[0570] gaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaact

[0571] gcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatggg

[0572] actttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcggtttgactcacggggatttcca

[0573] agtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggc

[0574] gtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgat

[0575] ccagcctccggtaccgaaaaccccggtccggctagcgccaccggatccggcggatctggcatggtgagcaagggcgaggagctgttcaccggggtggtgcccat

[0576] cctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgca

[0577] ccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttctt

[0578] caagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccc

[0579] tggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggc

[0580] cgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatc

[0581] ggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctgctggagttc

[0582] gtgaccgccgccgggatcactctcggcatggacgagctgtacaagggctccggagactacaaggatgacgatgacaaggattacaaagacgacgatgataagga

[0583] ctataaggatgatgacgacaaataaaagctttaaaccggttatcgataatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttac

[0584] gctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggccc

[0585] gttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccggaactttcgctttccccctc

[0586] cctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcc

[0587] tttccttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccg

[0588] gctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcgataccgagcgctgctcgagagatctacgggt

[0589] ggcatccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcctaataaaattaagttgcatcattttgtctgactaggt

[0590] gtccttctataatattatggggtggaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggcctgcggggtctattgggaaccaagctggagt

[0591] gcagtggcacaatcttggctcactgcaatctccgcctcctgggttcaagcgattctcctgcctcagcctcccgagttgttgggattccaggcatgcatgaccaggctca

[0592] gctaatttttgtttttttggtagagacggggtttcaccatattggccaggctggtctccaactcctaatctcaggtgatctacccaccttggcctcccaaattgctgggattac

[0593] aggcgtgaaccactgctcccttccctgtccttctgattttgtaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatggagttggccactccctctctg

[0594] cgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgagcgcgcagctgcctgcag

[0595] gggcgcccctcgaggactagtgaattcgtcgacctattaatattccggagtatacgtagccaaccactagaactatagctagagtcctgggcgaacaaacgatgctcg

[0596] ccttccagaaaaccgaggatgcgaaccacttcatccggggtcagcaccaccggcaagcgccgcgacggccgaggtcttccgatctcctgaagccagggcagatc

[0597] cgtgcacagcaccttgccgtagaagaacagcaaggccgccaatgcctgacgatgcgtggagaccgaaaccttgcgctcgttcgccagccaggacagaaatgcctc

[0598] gacttcgctgctgcccaaggttgccgggtgacgcacaccgtggaaacggatgaaggcacgaacccagttgacataagcctgttcggttcgtaaactgtaatgcaagt

[0599] agcgtatgcgctcacgcaactggtccagaaccttgaccgaacgcagcggtggtaacggcgcagtggcggttttcatggcttgttatgactgtttttttgtacagtctatgc

[0600] ctcgggcatccaagcagcaagcgcgttacgccgtgggtcgatgtttgatgttatggagcagcaacgatgttacgcagcagcaacgatgttacgcagcagggcagtc

[0601] gccctaaaacaaagttaggtggctcaagtatgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgag

[0602] ttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcg

[0603] gttgttggcgctctcgcggcttacgttctgcccaggtttgagcagccgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcagggcattg

[0604] ccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctatacaaa

[0605] gttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaacaattcgttcaagccgagatcggcttcccggccgcggagttgttcggtaa

[0606] attgtcacaacgccgcgaatatagtctttaccatgcccttggccacgcccctctttaatacgacgggcaatttgcacttcagaaaatgaagagtttgctttagccataacaa

[0607] aagtccagtatgctttttcacagcataactggactgatttcagtttacaactattctgtctagtttaagactttattgtcatagtttagatctattttgttcagtttaagactttattgt

[0608] ccgcccacacccgcttacgcagggcatccatttattactcaaccgtaaccgattttgccaggttacgcggctggtctgcggtgtgaaataccgcacagatgcgtaagg

[0609] agaaaataccgcatcaggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacgg

[0610] ttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccatagg

[0611] ctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcg

[0612] tgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgtaggtatctcagttcggtgta

[0613] ggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgactt

[0614] atcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagg

[0615] acagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgca

[0616] agcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcat

[0617] gagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagt

[0618] gaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgca

[0619] atgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctcca

[0620] tccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggt

[0621] atggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaa

[0622] gttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctg

[0623] agaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcg

[0624] gggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgag

[0625] caaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttatt

[0626] gtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgaaattgtaaacgttaatattttgtta

[0627] aaattcgcgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagatagggttgagtgttgttcc

[0628] agtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatcagggcgatggcccactacgtgaaccatcaccctaatcaa

[0629] gttttttggggtcgaggtgccgtaaagcactaaatcggaaccctaaagggagcccccgatttagagcttgacggggaaagccggcgaacgtggcgagaaaggaag

[0630] ggaagaaagcgaaaggagcgggcgctagggcgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacagggcgcgtc。

[0631] SEQ ID NO.16:

[0632] ATGCATtaccatcgcatacaacattatgaatacaaggggttgtgttaataataataaaatgatatttatgaatgctttgggcttgcaacctcaaagtaaattgaaattat

[0633] tgcacataaaatactagaaaaatgtaaacgtgacgcgtacacgcgtttcaagggcgtaaaggcgatcaagaatgaactaaaaacatacaatcttacgttgcaacaatac

[0634] aacgaggcgctcaatcagtgcgctttaaacgatagccgatggcgcgacacaaataattggcatcacgatattgaagaaggtgtgaaataaacaagagacatatatatagagttaattttaattctaaaacccaagaaattgaagaatattattacattaaagtagaatgttatgtaaacagttaaACTAGT。

[0635] SEQ ID NO.17:

[0636] Gcatgcttaatctacatttattgtaaacatttgtggtaatagtggcgttggttatacatttatatgattgtaatgttgtgtactcgttttgtaataaatttttgtgtttaatcaattcaata

[0637] tttttttgataaaaccttattttcgctactcaatttggcgtttttagacgcaagttttgcgtaatcgtcattgagcgattttagcgccttttcagttgtaattcgtttcagttgcaat

[0638] tctttaaaagatttatgcatgttgttgtagtcgcttttaattttgtctaacttttcttgcatagaaacgcttgtttgttgtaatttgtctaaatctaattgttgtttaatgttgagctgcgtttgttcggcaatgtctacctgtagtttttttagtatcgcttgtgcttcagacagcatagtgtcgtcggcatttgcgttgttgtcttcgtttaaac。

[0639] SEQ ID NO.18: 478bp

[0640] AtgcatCGCGCGCGacattaaagattacacatcgacgccccatcattttttccatcagtctaaaatttacaccaacagcgcggcgcccgacgaagactcgcaag

[0641] acgacagtaataccaccgtggtaattatcgctattgtcgctgcaatgatcctattctgtggattattgttatttttgttttgctgtataaaaaaacggtgtcatcaatcaaataac

[0642] gtggttgtgcaatacaaaaataacaatgaatttgtcacaatttgcaataatttagaagacaatcgagcatacattaatttacctaatgaatacgatagcgatgatatgccaaa

[0643] accattgtaccctttacttggctttaaatgatgatttgttaaaagatgataaacctgtgttgtaccctatgattatagaaaaataaaataaaacatgtataattgaaataaatatattatttaataaaatgttttttatactagt。

[0644] SEQ ID NO.19:

[0645] Gcatgcaatgttttttatttatatactattttctattacatattccaatgcacacaaatgtttaatggctatcagttttaattttactaattcgtctaaacaaaaattattcacttgctgt

[0646] ttttcatccatttgacatatggcgtttataaataattcgctgtgttttatgaacgaatcgtaaaccgctgcctgggccttcagcacggtcggcgcattgtatttttgggtaaagt

[0647] acgcaatatttttagtcaaacacagagattttaaatctttttcatttatatccaagtcggaacaaatcgtatacaaaatctagcttttcactttcgggcgcgcccagatactggtttacgagttcgagctgctccacttggcctttgatatcggccgctatgcacaacattttgtcgattgcagtgtttaaac。

[0648]

[0649]

[0650]

[0651] 2467..2778 = 312 bp: Homologous arm of HAR (ORF91); 4913..5311 = 399 bp: Homologous arm of HAL (lef4); Region between taa and tta marked in bold: 2782..4909 = 2128 bp inserted foreign gene.

[0652] SEQ ID NO.45 (12097 bp)

[0653] ccattcgccattcaggctgcaaataagcgttgatattcagtcaattacaaacattaataacgaagagatgacagaaaaattttcattctgtgacagagaaaaagtagccg

[0654] aagatgacggtttgtcacatggagttggcaggatgtttgattaaaaacataacaggaagaaaaatgccccgctgtgggcggacaaaatagttgggaactgggagggg

[0655] tggaaatggagtttttaaggattatttagggaagagtgacaaaatagatgggaactgggtgtagcgtcgtaagctaatacgaaaattaaaaatgacaaaatagtttggaa

[0656] ctagatttcacttatctggttcggatctcctaggctcgaggcatgcAGATCTGATCCAGACATGATAAGATACATTGATGAGTTTGG

[0657] ACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATT

[0658] TGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCA

[0659] GGGGGAGGTGTGGGAGGTTTTTTAAAGCAAGTAAAACCTCTACAAATGTGGTATGGCTGATTATGATC

[0660] CTCTAGTACTTCTCGACacctgatttaaatcatttattgttcaaagatgcagtcatccaaatccacattgaccagatcgcaggcagtgcaagcgtctggca

[0661] cctttcccatgatatgatgaatgtagcacagtttctgatacgcctttttgacgacagaaacgggttgagattctgacacgggaaagcactctaaacagtctttctgtccgtg

[0662] agtgaagcagatatttgaattctgattcattctctcgcattgtctgcagggaaacagcatcagattcatgcccacgtgacgagaacatttgttttggtacctgtctgcgtagt

[0663] tgatcgaagcCtccgcgtctgacgtcgatggctgcgcaactgactcgcgcacccgtttgggctcacttatatctgcgtcactgggggcgggtcttttcttggctccacc

[0664] ctttttgacgtagaattcatgctccacctcaaccacgtgatcctttgcccaccggaaaaagtctttgacttcctgcttggtgaccttcccaaagtcatgatccagacggcgg

[0665] gtgagttcaaatttgaacatccggtcttgcaacggctgctggtgttcgaaggtcgttgagttcccgtcaatcacggcgcacatgttggtgttggaggtgacgatcacggg

[0666] agtcgggtctatctgggccgaggacttgcatttctggtccacgcgcaccttgcttcctccgagaatggctttggccgactccacgaccttggcggtcatcttcccctcctc

[0667] ccaccagatcaccatcttgtcgacacagtcgttgaagggaaagttctcattggtccagtttacgcacccgtagaagggcacagtgtgggctatggcctccgcgatgttg

[0668] gtcttcccggtagttgcaggcccaaacagccagatggtgttcctcttgccgaactttttcgtggcccatcccagaaagacggaagccgcatattggggatcgtacccgt

[0669] ttagttccaaaattttataaatccgattgctggaaatgtcctccacgggctgctggcccaccaggtagtcgggggcggttttagtcaggctcataatctttcccgcattgtc

[0670] caaggcagccttgatttgggaccgcgagttggaggccgcattgaaggagatgtatgaggcctggtcctcctgAatccactgcttctccgaggtaatccccttgtccac

[0671] gagccacccgaccagctccatgtacctggctgaagtttttgatctgatcaccggcgcGtcagaattgggattctgattctctttgttctgctcctgcgtctgcgacacgtg

[0672] cgtcagatgctgcgccaccaaccgtttacgctccgtgagattcaaacaggcgcttaaatactgttccaAattagtccacgcccactggagctcaggctgggttttggg

[0673] gagcaagtaattggggatgtagcactcGtccaccaccttgttcccgcctccggcgccGtttctggtctttgtgaccgcgaaccagtttggcaaagtcggctcgatccc

[0674] gcggtaaattctctgaatcagtttttcgcgaatctgactcaggaaacgtcccaaaaccaAggatttcaccccggtggtttccacgagcacgtgcaAgtggaagtagct

[0675] ctctcccttctcaaattgcacaaagaaaagagcctccggggccttactcacacggcgccaCtccgtcagaaagtcgcgctgcagcttctcggccacggtcaggggt

[0676] gcctgctcaatcagattcagatccaAgtcagaatctggcggcaactcccaCtccttctcggccacccagttcacaaagctgtcagaaatgccgggcagatgctcgtc

[0677] aaggtcgctggggaccttaatcacaatctcgtaaaaccccgCcaGggcggcGACCGCGCCCGATGGTGGGACGGTATGAATAATC

[0678] CGTATTTATAGGTTTTTTTATTACAAAACTGTTACGAAAACAGTAAAATACTTATTTATTTGCGAGATGG

[0679] TTATCATTTTAATTATCTCCATGATCTATTAATATTCCTGCAGGCCGGAGTATACGGACCTTTAATTCAAC

[0680] CCAACACAATATATTATAGTTAAATAAGAATTATTATCAAATCATTTGTATATTAATTAAAATACTATACTG

[0681] TAAATTACATTTTATTTACAATCACTCGACcAAGACTTACACCCGGGggTtccgttaagGCCGCCACGGCTGC

[0682] CGACGGTTATCTACCCGATTGGCTCGAGGACAACCTCTCTGAGGGCATTCGCGAGTGGTGGGCtCTCA

[0683] AACCCGGCGCTCCTAAGCCAAAGGCTAACCAACAGAAACAAGACGACGGcCGCGGCCTtGTTCTCCC

[0684] CGGTTACAAATACCTcGGACCCTTCAACGGGCTcGACAAGGGCGAACCCGTGAACGCgGCGGACGCCG

[0685] CgGCCCTTGAGCACGATAAGGCTTACGACCAaCAACTcCAGGCCGGCGACAACCCTTACCTTCGTTATA

[0686] ACCACGCCGACGCcGAATTCCAGGAGCGTCTcCAAGAAGATACcTCTTTTGGGGGCAACCTCGGGCGA

[0687] GCAGTCTTCCAGGCCAAGAAGCGGGTTCTCGAACCTCTCGGTCTGGTTGAGGAAGGCGCTAAGACG

[0688] GCTCCTGGAAAGAAGAGACCGGTAGAGCCATCACCCCAGCGTTCTCCAGACTCCTCTACGGGCATCG

[0689] GCAAGAAAGGCCAACAGCCCGCCAGAAAAAGACTCAATTTTGGTCAGACTGGCGACTCAGAGTCAG

[0690] TTCCAGACCCTCAACCTCTCGGAGAACCTCCAGCAGCGCCCTCTGGTGTGGGACCTAATACAATGGCT

[0691] GCAGGCGGTGGCGCACCAATGGCAGACAATAACGAAGGCGCCGACGGAGTGGGTAGTTCCTCGGGA

[0692] AATTGGCATTGCGATTCCACATGGCTGGGCGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCC

[0693] TGCCCACCTACAACAACCACCTCTACAAGCAAATCTCCAACGGGACATCGGGAGGAGCCACCAACGA

[0694] CAACACCTACTTCGGCTACAGCACCCCCTGGGGGTATTTTGACTTTAACAGATTCCACTGCCACTTTTC

[0695] ACCACGTGACTGGCAGCGACTCATCAACAACAACTGGGGATTCCGGCCCAAGAGACTCAGCTTCAAG

[0696] CTCTTCAACATCCAGGTCAAGGAGGTCACGCAGAATGAAGGCACCAAGACCATCGCCAATAACCTCA

[0697] CCAGCACCATCCAGGTGTTTACGGACTCGGAGTACCAGCTGCCGTACGTTCTCGGCTCTGCCCACCAG

[0698] GGCTGCCTGCCTCCGTTCCCGGCGGACGTGTTCATGATTCCCCAGTACGGCTACCTAACACTCAACAA

[0699] CGGTAGTCAGGCCGTGGGACGCTCCTCCTTCTACTGCCTGGAATACTTTCCTTCGCAGATGCTGAGAA

[0700] CCGGCAACAACTTCCAGTTTACTTACACCTTCGAGGACGTGCCTTTCCACAGCAGCTACGCCCACAGC

[0701] CAGAGCTTGGACCGGCTGATGAATCCTCTGATTGACCAGTACCTGTACTACTTGTCTCGGACTCAAAC

[0702] AACAGGAGGCACGGCAAATACGCAGACTCTGGGCTTCAGCCAAGGTGGGCCTAATACAATGGCCAAT

[0703] CAGGCAAAGAACTGGCTGCCAGGACCCTGTTACCGCCAACAACGCGTCTCCAACGACAACCGGGCAA

[0704] AACAAATAGCAACTTTGCCTGGACTGCTGGGACCAAATACCATCTGAATGGAAGAAATTCATTGGC

[0705] TAATCCTGGCATCGCTATGGCAACACACAAAGACGACGAGGAGCGTTTTTTCCCAGTAACGGGATCC

[0706] TGATTTTTGGCAAACAAAATGCTGCCAGAGACAATGCGGATTACAGCGATGTCATGCTCACCAGCGAG

[0707] GAAGAAATCAAAACCACTAACCCTGTGGCTACAGAGGAATACGGTATCGTGGCAGATAACTTGCAGC

[0708] AGCAAAACACGGCTCCTCAAATTGGAACTGTCAAACAGCCAGGGGGCCTTACCCGGTATGGTCTGGCA

[0709] GAACCGGGACGTGTACCTGCAGGGTCCCATCTGGGCCAAGATTCCTCACACGGACGGCAACTTCCAC

[0710] CCGTCTCCGCTGATGGGCGGCTTTGGCCTGAAACATCCTCCGCCTCAGATCCTGATCAAGAACACGCC

[0711] TGTACCTGCGGATCCTCCGACCACCTTCAACCAGTCAAAGCTGAACTCTTTCATCACGCAATACAGCA

[0712] CCGGACAGGTCAGCGTGGAAATTGAATGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCCG

[0713] AGATCCAGTACACCTCCAACTACTACAAATCTACAAGTGTGGACTTTGCTGTTAATACAGAAGGCGTG

[0714] TACTCTGAACCCCGCCCCATTGGCACCCGTTACCTCACCCGTAATCTGTAAAGCTGGGGAGATGGGGG

[0715] AGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGA

[0716] CAGAATAAAACGCACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcgacatgtcctgcaggcagctgcgcgctcgctc

[0717] gctcactgaggccgcccgggcgtcgggcgacctttggtcgcccggcctcagtgagcgagcgagcgcgcagagagggagtggccaactccatcactaggggttcc

[0718] tgcggccgcacgcgtgtgtctagaacgcgtggagctagttattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacg

[0719] gtaaatggcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgg

[0720] gtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgc

[0721] ccagtacatgaccttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagcgg

[0722] tttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccattg

[0723] acgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagagctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccat

[0724] agaagacaccgggaccgatccagcctccggtaccgaaaaccccggtccggctagcgccaccggatccggcggatctggcatggtgagcaagggcgaggagct

[0725] gttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagc

[0726] tgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccac

[0727] atgaagcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtg

[0728] aagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacag

[0729] ccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccacta

[0730] ccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgat

[0731] cacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagggctccggagactacaaggatgacgatgacaaggattaca

[0732] aagacgacgatgataaggactataaggatgatgacgacaaataaaagctttaaaccggttatcgataatcaacctctggattacaaaatttgtgaaagattgactggtatt

[0733] cttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtct

[0734] ctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttc

[0735] cggaactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtg

[0736] ttgtcggggaaatcatcgtcctttccttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttc

[0737] cttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcatcgataccgagcgct

[0738] gctcgagagatctacgggtggcatccctgtgacccctccccagtgcctctcctggccctggaagttgccactccagtgcccaccagccttgtcctaataaaattaagtt

[0739] gcatcattttgtctgactaggtgtccttctataatattatggggtggaggggggtggtatggagcaaggggcaagttgggaagacaacctgtagggcctgcggggtcta

[0740] ttgggaaccaagctggagtgcagtggcacaatcttggctcactgcaatctccgcctcctgggttcaagcgattctcctgcctcagcctcccgagttgttgggattccagg

[0741] catgcatgaccaggctcagctaatttttgtttttttggtagagacggggtttcaccatattggccaggctggtctccaactcctaatctcaggtgatctacccaccttggcct

[0742] cccaaattgctgggattacaggcgtgaaccactgctcccttccctgtccttctgattttgtaggtaaccacgtgcggaccgagcggccgcaggaacccctagtgatgga

[0743] gttggccactccctctctgcgcgctcgctcgctcactgaggccgggcgaccaaaggtcgcccgacgcccgggctttgcccgggcggcctcagtgagcgagcgag

[0744] cgcgcagctgcctgcaggggcgcccctcgaggactagtgaattcgtcgacctattaatattccggagtatacgtagccaaccactagaactatagctagagtcctggg

[0745] cgaacaaacgatgctcgccttccagaaaaccgaggatgcgaaccacttcatccggggtcagcaccaccggcaagcgccgcgacggccgaggtcttccgatctcct

[0746] gaagccagggcagatccgtgcacagcaccttgccgtagaagaacagcaaggccgccaatgcctgacgatgcgtggagaccgaaaccttgcgctcgttcgccagc

[0747] caggacagaaatgcctcgacttcgctgctgcccaaggttgccgggtgacgcacaccgtggaaacggatgaaggcacgaacccagttgacataagcctgttcggttc

[0748] gtaaactgtaatgcaagtagcgtatgcgctcacgcaactggtccagaaccttgaccgaacgcagcggtggtaacggcgcagtggcggttttcatggcttgttatgact

[0749] gtttttttgtacagtctatgcctcgggcatccaagcagcaagcgcgttacgccgtgggtcgatgtttgatgttatggagcagcaacgatgttacgcagcagcaacgatgt

[0750] tacgcagcagggcagtcgccctaaaacaaagttaggtggctcaagtatgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctc

[0751] ttgatcttttcggtcgtgagttcggagacgtagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctg

[0752] ccttcgaccaagaagcggttgttggcgctctcgcggcttacgttctgcccaggtttgagcagccgcgtagtgagatctatatctatgatctcgcagtctccggcgagca

[0753] ccggaggcagggcattgccaccgcgctcatcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccg

[0754] cagtggctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaacaattcgttcaagccgagatcggcttcccggc

[0755] cgcggagttgttcggtaaattgtcacaacgccgcgaatatagtctttaccatgcccttggccacgcccctctttaatacgacgggcaatttgcacttcagaaaatgaaga

[0756] gtttgctttagccataacaaaagtccagtatgctttttcacagcataactggactgatttcagtttacaactattctgtctagtttaagactttattgtcatagtttagatctattttg

[0757] ttcagtttaagactttattgtccgcccacacccgcttacgcagggcatccatttattactcaaccgtaaccgattttgccaggttacgcggctggtctgcggtgtgaaatac

[0758] cgcacagatgcgtaaggagaaaataccgcatcaggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcact

[0759] caaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgtt

[0760] gctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttc

[0761] cccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcaatgctcacgctgta

[0762] ggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaac

[0763] ccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaacta

[0764] cggctacactagaaggacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagc

[0765] ggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgt

[0766] taagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagtt

[0767] accaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatc

[0768] tggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgc

[0769] aactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgt

[0770] cacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccga

[0771] tcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtact

[0772] caaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcat

[0773] tggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcacc

[0774] agcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaa

[0775] gcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgaaattgt

[0776] aaacgttaatattttgttaaaattcgcgttaaatttttgttaaatcagctcattttttaaccaataggccgaaatcggcaaaatcccttataaatcaaaagaatagaccgagata

[0777] gggttgagtgttgttccagtttggaacaagagtccactattaaagaacgtggactccaacgtcaaagggcgaaaaaccgtctatcagggcgatggcccactacgtgaa

[0778] ccatcaccctaatcaagttttttggggtcgaggtgccgtaaagcactaaatcggaaccctaaagggagccccgatttagagcttgacggggaaagccggcgaacgt

[0779] ggcgagaaaggaagggaagaaagcgaaaggagcgggcgctagggcgctggcaagtgtagcggtcacgctgcgcgtaaccaccacacccgccgcgcttaatgcgccgctacagggcgcgtc. 9363..9587=225bp: Tn7R homology arm; 183..348=166bp: Tn7R homology arm; the region between the two: 349..9362=9014bp of the inserted foreign gene.

[0780]

[0781]

[0782]

[0783]

[0784] 2467..2778=312bp: HAR (ORF91) homology arm; 11985..12383=399bp: HAL (lef4) homology arm; the region between taa and tta marked in bold: 2782..11981=9200bp inserted exogenous gene; 5093..7602=2510bpp10-Cap8-PA, of which 5252..7468=2217bp Cap8.

[0785]

[0786]

[0787]

[0788]

[0789] 2467..2778=312 bp: HAR (ORF91) homology arm; 8989..9387=399 bp: HAL (lef4) homology arm; the region between taa and tta marked in bold: 2782..8985=6204 bp: the inserted exogenous gene.

[0790]

[0791]

[0792]

[0793] 2462..2902=441 bp: HAR (cg30) homology arm; 8876..9272=397 bp: HAL (p15) homology arm; the region between taa and tta marked in bold: 2906..8872=5967 bp: the inserted exogenous gene.

[0794]

[0795]

[0796]

[0797] 2462..2860=399bp: HAR (pkip) homology arm; 8882..9288=407bp: HAL (port) homology arm; the region between taa and tta marked in bold includes: 2864..8830=5967bp of the inserted exogenous gene, and 8831..8878=48bp of non-coding 48bp.

[0798]

[0799]

[0800]

[0801] 342..748 = 407 bp: Homologous arm of HAL(prot); 4911..5309 = 399 bp: Homologous arm of HAR(pkip); Region between taa and tta marked in bold font: 752..4907 = 4156 bp inserted foreign gene.

[0802] SEQ ID NO.51(930 bp)

[0803] Actagtaaatcagtcacaccaaggcttcaataaggaacacacaagcaccatggtccatcatcaccaccatcactccgcgggatccctgcagaagcttatgggaatta

[0804] gccatggtccatatgaatatcctccttagttcctattccgaagttcctattctctagaaagtataggaacttcggcgcgcctacctgtgacggaagatcacttcgcagaata

[0805] aataaatcctggtgtccctgttgataccgggaagccctgggccaacttttggcgaaaatgagacgttgatcggcacgtaagaggttccaactttcaccataatgaaataa

[0806] gatcactaccgggcgtattttttgagttgtcgagattttcaggagctaaggaagctaaaatgttacgcagcagcaacgatgttacgcagcagggcagtcgccctaaaac

[0807] aaagttaggtggctcaagtatgggcatcattcgcacatgtaggctcggccctgaccaagtcaaatccatgcgggctgctcttgatcttttcggtcgtgagttcggagacg

[0808] tagccacctactcccaacatcagccggactccgattacctcgggaacttgctccgtagtaagacattcatcgcgcttgctgccttcgaccaagaagcggttgttggcgc

[0809] tctcgcggcttacgttctgcccaggtttgagcagccgcgtagtgagatctatatctatgatctcgcagtctccggcgagcaccggaggcagggcattgccaccgcgct

[0810] catcaatctcctcaagcatgaggccaacgcgcttggtgcttatgtgatctacgtgcaagcagattacggtgacgatcccgcagtggctctctctatacaaagttgggcatacgggaagaagtgatgcactttgatatcgacccaagtaccgccacctaaatttaaat.

[0811]

[0812]

[0813]

[0814] 342..748=407 bp: HAL (prot) homology arm; 4777..5175=399 bp: HAR (pkip) homology arm; the region between taa and tta marked in bold: 752..4773=4022 bp: the inserted exogenous gene.

[0815]

[0816]

[0817] 2462..2902=441bp: HAR (cg30) homology arm sequence; 6931..7327=397bp: HAL (p15) homology arm sequence; the region between taa and tta marked in bold: 2906..6927=4022bp inserted exogenous gene sequence.

[0818] SEQ ID NO.54 (2501 bp)

[0819] gtatacggacctttaattcaacccaacacaatatattatagttaaataagaattattatcaaatcatttgtatattaattaaaatactatactgtaaattacattttatttacaatcac

[0820] tcgacACTCGACGAAGACTTGATCACCCGGGGCCGCCCTGGCTGCCGACGGTTATCTACCCGATTGGCTC

[0821] GAGGACAACCTTAGTGAAGGAATTCGCGAGTGGTGGGCTTTGAAACCTGGAGCCCCTCAACCCAAG

[0822] GCAAATCAACAACATCAAGACAACGCTCGAGGTCTTGTGCTTCCGGGTTACAAATACCTTGGACCCG

[0823] GCAACGGACTCGACAAGGGGGAGCCGGTCAACGCAGCAGACGCGGCGGCCCTCGAGCACGACAAG

[0824] GCCTACGACCAGCAGCTCAAGGCCGGAGACAACCCGTACCTCAAGTACAACCACGCCGACGCCGAG

[0825] TTCCAGGAGCGGCTCAAAGAAGATACGTCTTTTGGGGGCAACCTCGGGCGAGCAGTCTTCCAGGCCA

[0826] AAAAGAGGCTTCTTGAACCTCTTGGTCTGGTTGAGGAAGCGGCTAAGACGGCTCCTGGAAAGAAGA

[0827] GGCCTGTAGAGCAGTCTCCTCAGGAACCGGACTCCTCCGCGGGTATTGGCAAATCGGGTGCACAGCC

[0828] CGCTAAAAAGAGACTCAATTTCGGTCAGACTGGCGACACAGAGTCAGTCCCAGACCCTCAACCAATC

[0829] GGAGAACCTCCCGCAGCCCCCTCAGGTGTGGGATCTCTTACAATGGCTTCAGGTGGTGGCGCACCAG

[0830] TGGCAGACAATAACGAAGGTGCCGATGGAGTGGGTAGTTCCTCGGGAAATTGGCATTGCGATTCCCAA

[0831] TGGCTGGGGGACAGAGTCATCACCACCAGCACCCGAACCTGGGCCCTGCCCACCTACAACAATCACC

[0832] TCTACAAGCAAATCTCCAACAGCACATCTGGAGGATCTTCAAATGACAACGCCTACTTCGGCTACAGC

[0833] ACCCCCTGGGGGTATTTTGACTTCAACAGATTCCACTGCCACTTCTCACCACGTGACTGGCAGCGACT

[0834] CATCAACAACAACTGGGGATTCCGGCCTAAGCGACTCAACTTCAAGCTCTTCAACATTCAGGTCAAA

[0835] GAGGTTACGGACAACAATGGAGTCAAGACCATCGCCAATAACCTTACCAGCACGGTCCAGGTCTTCA

[0836] CGGACTCAGACTATCAGCTCCCGTACGTGCTCGGGTCGGCTCACGAGGGCTGCCTCCCGCCGTTCCC

[0837] AGCGGACGTTTTCATGATTCCTCAGTACGGGTATCTGACGCTTAATGATGGAAGCCAGGCCGTGGGTC

[0838] GTTCGTCCTTTTACTGCCTGGAATATTTCCCGTCGCAAATGCTAAGAACGGGTAACAACTTCCAGTTCA

[0839] GCTACGAGTTTGAGAACGTACCTTTCCATAGCAGCTACGCTCACAGCCAAAGCCTGGACCGACTAATG

[0840] AATCCACTCATCGACCAATACTTGTACTATCTCTCAAAGACTATTAACGGTTCTGGACAGAATCAACAA

[0841] ACGCTAAAATTCAGTGTGGCCGGACCCAGCAACATGGCTGTCCAGGGAAGAAACTACATACCTGGAC

[0842] CCAGCTACCGACAACAACGTGTCTCAACCACTGTGACTCAAAACAACAACAGCGAATTTGCTTGGCC

[0843] TGGAGCTTCTTCTTGGGCTCTCAATGGACGTAATAGCTTGATGAATCCTGGACCTGCTATGGCCAGCCA

[0844] CAAAGAAGGAGAGGACCGTTTCTTTCCTTTGTCTGGATCTTTAATTTTTGGCAAACAAGGAACTGGAA

[0845] GAGACAACGTGGATGCGGACAAAGTCATGATAACCAACGAAGAAGAAATTAAAACTACTAACCCGGT

[0846] AGCAACGGAGTCCTATGGACAAGTGGCCACAAACCACCAGAGTGCCCAAGCACAGGCGCAGACCGG

[0847] CTGGGTTCAAAACCAAGGAATACTTCCGGGTATGGTTTGGCAGGACAGAGATGTGTACCTGCAAGGA

[0848] CCCATTTGGGCCAAAATTCCTCACACGGACGGCAACTTTCACCCTTCTCCGCTGATGGGAGGGTTTGG

[0849] AATGAAGCACCCGCCTCCTCAGATCCTCATCAAAAACACACCTGTACCTGCGGATCCTCCAACGGCCT

[0850] TCAACAAGGACAAGCTGAACTCTTTCATCACCCAGTATTCTACTGGCCAAGTCAGCGTGGAGATCGA

[0851] GTGGGAGCTGCAGAAGGAAAACAGCAAGCGCTGGAACCCGGAGATCCAGTACACTTCCAACTATTAC

[0852] AAGTCTAATAATGTTGAATTTGCTGTTAATACTGAAGGTGTATAGTGAACCCCGCCCCATTGGCACC

[0853] AGATACCTGACTCGTAATCTGTAAAGCTGGGGGAGATGGGGGAGGCTAACTGAAACACGGGAAGGAGA

[0854] CAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcG。157..2367=2211bp:Cap9 sequence。

[0855] SEQ ID NO.55(2465bp)

[0856] gtatacggacctttaattcaacccaacacaatatattatagttaaataagaattattatcaaatcatttgtatattaattaaaatactatactgtaaattacattttattttacaatcac

[0857] tcgacACTCGACGAAGACTTGATCACCCGGGGCCGCCCTGGCTTTTGTTGATCACCCaCCcGATTGGTTG

[0858] GAAGAAGTTGGTGAAGGTCTTCGCGAGTTTTTGGGCCTTGAAGCGGGCCCACCGAAACCAAAACCC

[0859] AATCAGCAGCATCAAGATCAAGCCCGTGGTCTTTGTGCTcCCTGGTTATAACTATTCTCGGACCCGGAAAC

[0860] GGTCTCGATCGAGGAGAGCCcGTCAACAGGGCAGACGAGGTCCGCGGAGAGCACGACATCTCGTAC

[0861] AACGAGCAGCTTGAGGCGGGAGACAACCCCTACCTCCAAGTACAACCACGCGGACGCCGAGTTTCAG

[0862] GAGAAGCTCGCCGACGACACATCCTTCGGGGGAAACCTCGGAAAGGCAGTCTTTCAGGCCAAGAAA

[0863] AGGGTTCTCGAACCTTTTGGCCTGGTTGAAGAGGGTGCTAAGACGGCCCCTACCGGAAAGCGGATAG

[0864] ACGACCACTTTCCAAAAAGAAAGAAGGCTCGGACCGAAGAGGACTCCAAGCCTTCCACCTCGTCAG

[0865] ACGCCGAAGCTGGACCCAGCGGATCCCAGCAGCTGCAAATCCCAGCCCAACCAGCCTCAAGTTTGGG

[0866] AGCTGATACAATGTCTGCGGGAGGTGGCGGCCCATTGGGCGACAATAACCAAGGTGCCGATGGAGTG

[0867] GGCAATGCCTCGGGAGATTGGCATTGCGATTCCACGTGGATGGGGGACAGAGTCGTCACCAAGTCCA

[0868] CCCGAACCTGGGTGCTGCCCAGCTACAACAACCACCAGTACCGAGAGATCAAAAGCGGCTCCGTCG

[0869] ACGGAAGCAACGCCAACGCCTACTTTGGATACAGCACCCCCTGGGGGTACTTTGACTTTAACCGCTTC

[0870] CACAGCCACTGGAGCCCCCGAGACTGGCAAAGACTCATCAACAACTACTGGGGCTTCAGACCCCGGT

[0871] CCCTCAGAGTCAAAATCTTCAACATTCAAGTCAAAGAGGTCACGGTGCAGGACTCCACCACCACCAT

[0872] CGCCAACAACCTCACCTCCACCGTCCAAGTGTTTACGGACGACGACTACCAGCTGCCCTACGTCGTC

[0873] GGCAACGGGACCGAGGGATGCCTGCCGGCCTTCCCTCCGCAGGTCTTTACGCTGCCGCAGTACGGTT

[0874] ACGCGACGCTGAACCGCGACAACACAGAAAATCCCACCGAGAGGAGCAGCTTCTTCTGCCTAGAGT

[0875] ACTTTCCCAGCAAGATGCTGAGAACGGGCAACAACTTTGAGTTTACCTACAACTTTGAGGAGGTGCC

[0876] CTTCCACTCCAGCTTCGCTCCCAGTCAGAACCTGTTCAAGCTGGCCAACCCGCTGGTGGACCAGTAC

[0877] TTGTACCGCTTCGTGAGCACAAATAACACTGGCGGAGTCCAGTTCAACAAGAACCTGGCCGGGAGAT

[0878] ACGCCAACACCTACAAAAACTGGTTCCCGGGGCCCATGGGCCGAACCCAGGGCTGGAACCTGGGCT

[0879] CCGGGGTCAACCGCGCCAGTGTCAGCGCCTTCGCCACGACCAATAGGATGGAGCTCGAGGGCGCGA

[0880] GTTACCAGGTGCCCCCGCAGCCGAACGGCATGACCAACAACCTCCAGGGCAGCAACACCTATGCCCT

[0881] GGAGAACACTATGATCTTCAACAGCCAGCCGGCGAACCCGGGCACCACCGCCACGTACCTCGAGGGC

[0882] AACATGCTCATCACCAGCGAGAGCGAGACGCAGCCGGTGAACCGCGTGGCGTACAACGTCGGCGGG

[0883] CAGATGGCCACCAACAACCAGAGCTCCACCACTGCCCCCGCGACCGGCACGTACAACCTCCAGGAA

[0884] ATCGTGCCCGGCAGCGTGTGGATGGAGAGGGACGTGTACCTCCAAGGACCCATCTGGGCCAAGATCC

[0885] CAGAGACGGGGGCGCACTTTCACCCCTCTCCGGCCATGGGCGGATTCGGACTCAAACACCCACCGCC

[0886] CATGATGCTCATCAAGAACACGCCTGTGCCCGGAAATATCACCAGCTTCTCGGACGTGCCCGTCAGCA

[0887] GCTTCATCACCCAGTACAGCACCGGGCAGGTCACCGTGGAGATGGAGTGGGAGCTCAAGAAGGAAA

[0888] ACTCCAAGAGGTGGAACCCAGAGATCCAGTACACAAACAACTACAACGACCCCCAGTTTGTGGACTT

[0889] TGCCCCGGACAGCACCGGGGAATACAGAACCACCAGACCTATCGGAACCCGATACCTTACCCGACCC

[0890] CTTTAAAGCTGGGGAGATGGGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCC

[0891] GCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcG. 157..2331 = 2175bp: Cap5 sequence.

[0892] SEQ ID NO.56(2501bp)

[0893] GTATACGGACCTTTAATTCAACCCAACACAATATATTATAGTTAAATAAGAATTATTATCAAATCATTTGT

[0894] ATATTAATTAAAATACTATACTGTAAATTACATTTTATTTACAATCactcgacACTCGACGAAGACTTGATCA

[0895] CCCGGGGCCGCCCTGgctgccgaCggttatctAccCgattggctcgaggacactctctcCgaaggaataagacagtggtggaagctcaaacctggc

[0896] ccaccaccaccaaagcccgcagagcggcataaggacgacagcaggggtcttgtgcttcctgggtacaagtacctcggacccttcaacggactcgacaagggaga

[0897] gccggtcaacgaggcagacgccgcggccctcgagcacgacaaagcctacgaccggcagctcgacagcggagacaacccgtacctcaagtacaaccacgccga

[0898] cgcggagtttcaggagcgccttaaagaagatacCtcttttgggggcaacctcggacgagcagtcttccaggcgaaaaagagggttcttgaacctctCggcctggttg

[0899] aggaacctgttaagacggctccgggaaaaaagaggccggtagagcactctcctgtggagccagactcctcctcgggaaccggaaaggcgggccagcagcctgc

[0900] aagaaaaagattgaattttggtcagactggagacgcagactcagtacctgacccccagcctctcggacagccaccagcagccccctctggtctgggaactaatacga

[0901] tggctacaggcagtggcgcaccaatggcagacaataacgagggcgccgacggagtgggtaattcctcgggaaattggcattgcgattccacatggatgggcgaca

[0902] gagtcatcaccaccagcacccgaacctgggccctgcccacctacaacaaccacctctacaaacaaatttccagccaatcaggagcctcgaacgacaatcactacttt

[0903] ggctacagcaccccttgggggtattttgacttcaacagattccactgccacttttcaccacgtgactggcaaagactcatcaacaacaactggggattccgacccaaga

[0904] gactcaacttcaagctctttaacattcaagtcaaagaggtcacgcagaatgacggtacgacgacgattgccaataaccttaccagcacggttcaggtgtttactgactcg

[0905] gagtaccagctcccgtacgtcctcggctcggcgcatcaaggatgcctcccgccgttcccagcagacgtcttcatggtgccacagtatggatacctcaccctgaacaac

[0906] gggagtcaggcagtaggacgctcttcattttactgcctggagtactttccttctcagatgctgcgtaccggaaacaactttaccttcagctacacttttgaggacgttccttt

[0907] ccacagcagctacgctcacagccagagtctggaccgtctcatgaatcctctcatcgaccagtacctgtattacttgagcagaacaaacactccaagtggaaccaccac

[0908] gcagtcaaggcttcagttttctcaggccggagcgagtgacattcgggaccagtctaggaactggcttcctggaccctgttaccgccagcagcgagtatcaaagacatc

[0909] tgcggataacaacaacagtgaatactcgtggactggagctaccaagtaccacctcaatggcagagactctctggtgaatccgggcccggccatggcaagccacaag

[0910] gacgatgaagaaaagttttttcctcagagcggggttctcatctttgggaagcaaggctcagagaaaacaaatgtggacattgaaaaggtcatgattacagacgaagag

[0911] gaaatcaggacaaccaatcccgtggctacggagcagtatggttctgtatctaccaacctccagagaggcaacagacaagcagctaccgcagatgtcaacacacaag

[0912] gcgttcttccaggcatggtctggcaggacagagatgtgtaccttcaggggcccatctgggcaaagattccacacacggacggacattttcacccctctcccctcatgg

[0913] gtggattcggacttaaacaccctcctccacagattctcatcaagaacaccccggtacctgcgaatccttcgaccaccttcagtgcggcaaagtttgcttccttcatcacac

[0914] agtactccacgggacaggtcagcgtggagatcgagtgggagctgcagaaggaaaacagcaaacgctggaatcccgaaattcagtacacttccaactacaacaagt

[0915] ctgttaatgtggactttatactgtggacactaatggcgtgtattcagagcctcgccccattggcaccagatacctgactcgtaatctgtaaAGCTGGGGAGATG

[0916] GGGGAGGCTAACTGAAACACGGAAGGAGACAATACCGGAAGGAACCCGCGCTATGACGGCAATAAAAAGACAGAATAAAACGCACGGGTGTTGGGTCGTTTGTTCCCTCGAcgcgccggcg. 157..2367=2211bp: Cap2 sequence.

[0917] The various technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. In order to make the description concise, not all possible combinations of the various technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of the description in this specification.

[0918] The above-described embodiments only express several implementation methods of the present application, which facilitate a specific and detailed understanding of the technical solutions of the present application, but cannot be understood as limiting the scope of protection of the patent application. It should be pointed out that, for ordinary technicians in this field, without departing from the concept of the present application, several variations and improvements can be made, which all fall within the scope of protection of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the scope of protection of the present application. It should also be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided in the present application are all within the scope of protection of the claims attached to the present application. Therefore, the scope of protection of the patent application of the present application shall be based on the content of the attached claims, and the description and drawings can be used to interpret the content of the claims.

Claims

1. A nucleic acid molecule, characterized in that The nucleic acid molecule comprises: a nucleic acid fragment 1, a nucleic acid fragment 2 and an exogenous gene expression frame for expressing an exogenous fragment located between the nucleic acid fragment 1 and the nucleic acid fragment 2; The complementary fragments of the nucleic acid fragment 1 and the nucleic acid fragment 2 are a tail-to-tail gene pair; The tail-to-tail gene pair is the env-prot gene and the pkip gene, which are connected via the non-coding region shown in SEQ ID NO.

1. The exogenous gene expression frame is inserted into any site in the non-coding region shown in SEQ ID NO.1, which is recorded as the OB3 site.

2. The nucleic acid molecule according to claim 1, characterized in that The tail-to-tail gene pair is from a baculovirus.

3. The nucleic acid molecule according to claim 1, characterized in that The exogenous fragments include one or more of a selection marker gene and a target gene.

4. The nucleic acid molecule according to claim 3, characterized in that The exogenous gene expression cassette satisfies one or more of the following conditions 1) and 2): 1) the exogenous gene expression frame includes a promoter regulating the selection marker gene including a baculovirus very early promoter; and, 2) The exogenous gene expression frame includes a promoter that regulates the target gene, including a P10 promoter or a PH promoter.

5. The nucleic acid molecule according to claim 3, characterized in that The exogenous fragment satisfies one or more of the following conditions (A) and (B): (A) the selection marker gene comprises one or more of a luciferase gene, a neomycin resistance gene, a hygromycin phosphotransferase gene, a dihydrofolate reductase gene, a thymidine kinase gene, a glutamine synthetase gene, an asparagine synthetase gene, a tryptophan synthetase gene, a histidinol dehydrogenase gene, an aminoglycoside phosphotransferase gene, and a tryptophan synthetase gene; and, (B) The target gene encodes one or more of an antibody, a polypeptide, an enzyme, a hormone, a growth factor and a protein receptor.

6. The nucleic acid molecule according to any one of claims 1 to 5, characterized in that The sequence of the nucleic acid molecule is shown in SEQ ID NO.49, 2861 bp to 8881 bp, SEQ ID NO.50, 749 bp to 4910 bp, SEQ ID NO.52, 749 bp to 4776 bp, or SEQ ID NO.53, 2903 bp to 6930 bp.

7. A recombinant plasmid, characterized in that The recombinant plasmid comprises the nucleic acid molecule according to any one of claims 1 to 6.

8. A recombinant baculovirus, characterized in that The genome of the recombinant baculovirus comprises the nucleic acid molecule according to any one of claims 5 to 6.

9. The recombinant baculovirus according to claim 8, characterized in that The recombinant baculovirus satisfies one or more of the following conditions A) and B): A) the recombinant baculovirus is Spodoptera californica nuclear polyhedrosis virus, Bombyx mori nuclear polyhedrosis virus, Pseudococcidae multiple nucleocapsid nuclear polyhedrosis virus, Gypsy moth multiple nucleocapsid nuclear polyhedrosis virus, Spodoptera exigua multiple nucleocapsid nuclear polyhedrosis virus, Helicoverpa armigera nuclear polyhedrosis virus or Spodoptera litura nuclear polyhedrosis virus; and, B) The foreign gene expression cassette defined in any one of claims 1 to 6 is inserted into other gene loci of the genome of the recombinant baculovirus.

10. The recombinant baculovirus according to claim 9, characterized in that The selection marker gene is inserted into any one of the OB1 site, the OB2 site and the OB3 site; The lef4 gene and the orf91 gene form a tail-to-tail gene pair, and the lef4 gene and the orf91 gene are connected by the noncoding region taatta, and the position between taa and tta is recorded as the OB1 site; The p15 gene and the cg30 gene form a tail-to-tail gene pair. The p15 gene and the cg30 gene are connected by the non-coding region taatta, and the position between taa and tta is recorded as the OB2 site.

11. The method for constructing a recombinant baculovirus according to any one of claims 8 to 10, characterized in that: The construction method comprises the following steps: causing homologous recombination between the donor plasmid and the baculovirus genome, thereby constructing a recombinant baculovirus; The donor plasmid comprises a nucleic acid fragment consisting of the nucleic acid molecule according to any one of claims 1 to 6.

12. The method for constructing a recombinant baculovirus according to claim 11, characterized in that: The recombinase used for homologous recombination is RED recombinase, Bxb1 integrase, ΦC31 integrase, Cre recombinase or FLP recombinase.

13. The method for constructing a recombinant baculovirus according to any one of claims 11 to 12, characterized in that: The donor plasmid includes a shuttle plasmid.

14. An adeno-associated virus packaging vector system, characterized in that: It comprises essential elements for AAV packaging, which include one or more of Cap gene, Rep gene and ITR gene; the essential elements for AAV packaging are located in the same or different nucleic acid molecules according to any one of claims 1 to 6.

15. A method for producing an expression product of an exogenous fragment, characterized in that: The production method comprises the following steps: The recombinant baculovirus according to any one of claims 8 to 10 is used to infect host cells and then cultured, and the expression product of the exogenous fragment is separated from the obtained culture product.

16. The method for producing the expression product of the exogenous fragment according to claim 15, characterized in that: Such host cells include insect cell lines.

17. The method for producing the expression product of the exogenous fragment according to claim 16, characterized in that: The insect cell lines include Lepidoptera insect cell lines.

18. The method for producing the expression product of the exogenous fragment according to any one of claims 15 to 17, characterized in that: The production method further comprises the step of detecting the titer of the obtained recombinant baculovirus; The titer was detected using the standard curve method, which includes the following steps: Providing a standard curve, wherein the standard curve reflects the linear relationship between the luciferase activity value and the virus titer value; and, Detecting the activity value of luciferase expressed by the luciferin gene in the recombinant baculovirus to be tested, substituting it into the standard curve, and calculating the virus titer value of the recombinant baculovirus to be tested; The activity value of the luciferase = the luminescence intensity value generated by the luciferase expressed by the recombinant baculovirus - the luminescence intensity value of the virus-free control substance.

19. A method for producing a recombinant adeno-associated virus, characterized in that: The production method adopts the adeno-associated virus packaging vector system described in claim 14.